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Abstract 
 
Background 
Bariatric surgery has been shown to be safe and effective for the treatment of morbid obesity (BMI > 40 
kg/m2) and some related comorbidities. The goal of the current study is to explore the role of surgery in 
patients with moderate obesity (BMI < 35 kg/m2).  
Methods 
Systematic review and meta analysis was performed focusing solely on patients with BMI < 35 kg/m2 who 
underwent laparoscopic roux en y gastric bypass (RYGB), sleeve gastrectomy (LSG), or adjustable gastric 
banding (AGB). Data were limited to randomized controlled trials (RCT) and prospective cohort studies. 
Primary outcome measure was fasting plasma glucose (FPG). Secondary outcome measures included 
hemoglobin A1c (HbA1c), and other obesity related comorbidities.  
Results 
13 studies were included in the analysis, 4 randomized controlled trials and 9 prospective cohort studies. 
Surgery was associated with significantly improved FPG compared to medical therapy (weighted mean 
difference (WMD) -3.24, 95% confidence interval (CI) -4.45; -2.02). Surgery was also associated with 
improved HbA1c, body weight, BMI loss, waist circumference, and resolution of hypertension and 
dyslipidemia. These results were consistent across each surgical procedure. 2 RCTs compared RYGB to 
LSG.  There was no difference with respect to glucose metabolism however RYGB was associated with 
greater BMI loss (WMD -1.07, 95% CI -1.81; -0.33) and decreased waist circumference (WMD -3.51, 95% 
CI -6.99; -0.03). Complication rates were comparable to morbidly obese subjects.  
Conclusion 
RYGB, LSG and AGB appear to be safe and effective in the treatment of obesity and related comorbidities 
and should be offered to patients with BMI < 35. RYGB and LSG have similar effects on FPG and HbA1c 
however REYGB appears to have improved results with respect to waist circumference and BMI.  
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Introduction 
Obesity is one of the most threatening health issues seen today and is defined as 
having abnormal or excessive fat accumulation. In 2016, 1.9 billion adults worldwide 
were overweight.  Of these, 650 million persons were obese. Obesity is a risk factor for 
cardiovascular disease, musculoskeletal disorders, cancer and premature death1. Body 
Mass index (BMI) is a very commonly used measure of weight versus height and is used 
to classify individuals as overweight or obese. It is calculated as a persons weight in 
kilograms divided by the square of their height in meters (kg/m2). Ideal BMI is between 
18.5-25. Overweight individuals are defined as BMI between 25.1-30. Obesity is defined 
as a BMI between 30-40 and these patients are further classified into class I obesity (BMI 
30.1-35) and class II obese (BMI 35.1-40).  The term ‘moderate obesity’ is used to 
describe patients with BMI 30-35 and we use the term morbid obesity to describe 
individuals with BMI > 40.  The advantage of using BMI as a measure of obesity is that it 
is easily calculated for most patients and is commonly accepted as a measure of obesity 
so it brings with it generalizability. However, BMI tends to overestimate for large frame 
individuals and underestimate for shorter individuals. BMI also does not take into 
account muscle mass versus fat mass, which also can also provide some limitations2. 
Surgical management of obesity was first conceived in the 1950’s. This began 
with the observation that patients who lost various lengths of small intestine lost weight 
despite increased caloric intake. This was also noted in various experiments involving 
intestinal resection in dogs, which caused fat malabsorption and weight loss. A similar 
observation was made in patients who lost part or all of their stomach, which was 
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typically associated with a significant degree of weight loss. These observations led to the 
development of surgically induced weight loss for overweight and obese individuals2. 
The term ‘bariatric’ comes from the Greek ‘baro’ meaning pressure and is defined 
as the branch of medicine pertaining to the prevention and treatment of obesity, thus the 
term bariatric surgery or also metabolic surgery, as many of these procedures will have 
profound metabolic effects on the body. Excess body weight can be calculated using 
metropolitan life tables for ideal body weight for height3. We can therefore calculate 
excess weight loss post intervention and this is commonly used as a measure of success 
following bariatric surgery.  Various procedures have been developed over time and rates 
of excess weight loss have varied from 25-85%4. 
Bariatric surgery has also been shown to be associated with resolution of obesity 
related comorbidities such as diabetes mellitus, hypertension, hypercholesterolemia, sleep 
apnea and arthritis5. Typically for any given procedure the rate of resolution of 
comorbidities tends to parallel the rates of excess weight loss. Procedures are generally 
categorized as having restrictive effects if the proximal gastrointestinal tract is modified 
to limit intake, or malabsorptive effects if a portion of the small intestine is excised or 
bypassed. Various procedures can also have a combination of restrictive and 
malabsorptive effects6.  
Surgery is associated with certain morbidity and mortality, and when considering 
any surgical intervention one must weigh the risk of surgery versus the potential benefit. 
With respect to obesity, surgery has been shown to be an effective tool in sustaining 
weight loss and in treating obesity related comorbidities such as Diabetes mellitus (DM), 
hypertension, hypercholesterolemia, obstructive sleep apnea and osteoarthritis. Obese 
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patients typically have higher than average risk for perioperative complications and some 
series report mortality rates as high as 2-3%, which is much higher than for most elective 
surgeries7. Most early studies explored the effects of bariatric surgery on patients who 
were morbidly obese (BMI >40) or class II obese (BMI >35) with significant 
comorbidities and in 1994 the National institute of health (NIH) developed consensus 
guidelines restricting access to bariatric surgery to these patients8.  
More recent evidence has revealed that patients who are overweight or class I 
obese (BMI 25-35) may also benefit from bariatric surgery, particularly those patients 
afflicted with diabetes. On the basis of some of these early studies the NIH published 
revised guidelines, which made allowances for these patients in the setting of a clinical 
trial9. This created some controversy in providing a surgical intervention with associated 
risks to a patient population where the absolute benefit is unclear. Much of the data to 
date is from retrospective studies with small numbers of patients and because of this we 
felt that a systematic review of the literature and meta analysis would be necessary to 
fully explore the effect of bariatric surgery in patients with BMI less than 35. On this 
basis the objectives of our study are (1) To determine the efficacy and safety of bariatric 
surgery in patients with a BMI < 35 kg/m2 (2) To determine whether one surgical 
procedure will be superior in this patient population and (3) To fully explore the effect of 
surgery on less well studied obesity related comorbidities such as sleep apnea and 
osteoarthritis in patients with BMI < 35.  
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Chapter 1 - Background 
1.1 Open surgery era 
Many surgical procedures in the abdomen are performed through a very large 
incision in the abdominal wall through which surgeons can manipulate organs directly 
with their hands or surgical instruments. This is commonly referred to as ‘open’ surgery. 
This term is often used to differentiate from laparoscopic surgery, which involves intra 
abdominal surgery through very small incisions and using longer instruments.  Up until 
the early 1980s abdominal surgery was done almost exclusively via the open approach. In 
1963 Payne et. al. performed the first surgical procedure for obesity, which was the 
jejunocolic bypass. This involved division of the proximal small bowel approximately 
50cm down stream and connecting the proximal small bowel segment to the mid 
transverse colon. The distal small bowel segment was closed leaving a long blind loop. 
Later, the procedure was modified by changing the site for the anastomosis to the 
ascending colon as the initial procedure was associated with significant diarrhea. Despite 
this modification the jejunocolic bypass was associated with significant steattorhea or 
loss of fat in the stool, dehydration, electrolyte imbalances, perianal complications, 
hepatic cirrhosis or scarring of the liver and subsequent hepatic failure. Despite 
reasonable weight loss and resolution of obesity related comorbidities the procedure was 
largely abandoned because of these complications6.  
In 1969 Payne and DeWind described the jejunoileal bypass. This involved a 
bypass of a large portion of the small intestine without proximal restriction. This 
approach was initially used to treat super obese patients or those with BMI > 60kg/m2. 
This procedure was associated with significant weight loss and resolution of obesity 
related comorbidities but also led to significant long-term complications such as  
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Steatorrhea, kidney stones, abdominal distension, and hepatic failure secondary to protein 
malabsorption. Hepatic failure was one of the most serious complications of this 
procedure and initial mortality rates over the first 2 years were around 4%. These 
complications ultimately led to this operation being superseded by other procedures. In 
fact most patients who have undergone jejunoileal bypass subsequently went on to have 
this procedure reversed and converted to an alternative procedure in an attempt to avoid 
some of these long term complications2.  
Gastric bypass (Appendix 1 and 2) was developed out of the observation that 
patients post gastric surgery lost significant amounts of weight. Mason and colleagues 
conceived the procedure of gastric bypass in the 1967. This involved construction of a 
small approximately 30ml gastric pouch via gastric partition. This was initially performed 
using staplers that would occlude the stomach but not physically divide it. The procedure 
also involves division of the small bowel approximately 40cm down stream and creation 
of a 100cm alimentary limb which is approximated to the gastric pouch10. In 1977 Alden 
and colleagues altered the procedure by using alternate stapling devices, which would 
physically divide the stomach.11. Long term data on patients undergoing gastric bypass 
have been published over 25 years of follow up and have shown that excess weight loss is 
in the 60-70% range and has been sustainable over time. This makes gastric bypass the 
traditional gold standard procedure in bariatric surgery12. Over the years various forms of 
gastric partition were created in an attempt to simplify the operation. These procedures 
involved the use of various types of mesh and stapling devices. Although associated with 
significant weight loss initially, long term complications such as mesh erosion, stricture, 
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pouch dilation, esophageal dilation, staple line dehiscence and weight regain led to these 
modifications falling out of favor13.  
Biliopancreatic diversion (BPD) is an alternative procedure developed to maintain 
the restrictive effect of the gastric bypass while enhancing the malabsorptive effect and 
was initially described by Scopinaro in 1979.  This procedure differs from the gastric 
bypass in that rather than dividing the stomach, a portion of the stomach is removed and 
similarly to gastric bypass the small bowel is divided and connected to the gastric pouch.  
This procedure provided excellent long-term weight loss with rates of excess weight loss 
of 85%, however was associated with very severe protein and micronutrient 
malabsorption14. 
 In the 1993 Marceaux and colleagues refined the biliopancreatic diversion 
procedure creating the duodenal switch procedure. This procedure was initially described 
as a two-part procedure. The first part consisted of a sleeve gastrectomy, which is 
resecting about 70% of the stomach leaving a narrow sleeve (Appendix 3). The second 
part of the procedure would essentially involve bypass of the small bowel. This was in an 
attempt to maintain excellent weight loss but limit the severe protein and micronutrient 
malabsorption. Biliopancreatic diversion and similar procedures are performed less 
commonly, likely because of reports of mortality of greater than 2%, which is 
substantially higher than other metabolic surgeries14.  
 
1.2 Laparoscopic surgery era  
Laparoscopic surgery refers to performing abdominal surgeries through small 
incisions around 5-10mm and using small instruments and a camera that pass through 
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these incisions. Initially developed in 1980 this approach has become the standard of care 
for many surgical procedures and has produced tremendous results including decreased 
pain and quicker recovery for most patients compared to traditional open approach.  For 
many years open gastric bypass was the standard of care. In the early 1990’s the 
laparoscopic approach simplified these operations and led to significant improvements in 
patient morbidity, hospital stay and return to normal activities15. Today the laparoscopic 
approach has become the standard of care in bariatric surgery. The 1990’s also saw the 
invention of the adjustable gastric band (Appendix 4). This consists of a hollow tubing, 
which is placed around the stomach to create a restrictive effect where patients would 
only be able to consume small amounts of food. The tubing is connected to a 
subcutaneous port through which saline can be injected or withdrawn thereby adjusting 
the restrictive effect of the pouch. Excess weight loss is in the range of 25-35%. While 
the short term complication rate is favorable, excess weight loss can be substantially 
lower compared to some other procedures and that the re-operative rate for these patients 
can be as high as 40%12.  
An interesting observation in patients undergoing the duodenal switch operation 
was that many patients lost a significant amount of weight, and in fact approximately half 
did not require any further surgery. This led to the idea that the sleeve gastrectomy 
portion of the procedure could be a stand-alone bariatric procedure. Laparoscopic sleeve 
gastrectomy (LSG) is associated with excellent weight loss and resolution of obesity 
related comorbidities, and very low complication rates. In 2001, Sleeve gastrectomy was 
described as a stand-alone procedure. This procedure does carry a risk of 
gastroesophageal reflux and staple line leak however these appear to be uncommon. 
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Excess weight loss appears to be around 60%, which is comparable to gastric bypass 
however long term data are lacking. When performed laparoscopically this procedure has 
been shown to be a safe and effective treatment for obesity and related comorbidities16.  
There is much debate in the literature and in the bariatric community about which 
procedure is superior and certainly there are factors which may make one procedure more 
appropriate for any given patient. Varying degrees of excess weight loss, perioperative 
morbidity, complications, and long-term results have led to such controversies. In 1994 
the National Institute of Health developed guidelines regarding which patients would be 
eligible for bariatric surgery. It was felt that patients with a ‘BMI over 40’ or ‘greater 
then 35 with at least one obesity related comorbidity’ would be eligible. These guidelines 
were developed based on the best available evidence at the time. Bariatric surgery in this 
patient population has been shown to be safe and effective in sustaining long-term weight 
loss and resolution of comorbidities17.  
 
1.3 Surgery for moderate Obesity 
 Diabetes Mellitus along with other obesity related comorbidities are serious 
conditions with potentially devastating complications that affects all age groups. In 2012 
the International Diabetes Federation (IDF) estimated that 371 million people worldwide 
were afflicted with diabetes. That number is expected to rise to 552 million by 2030. 
Diabetes is the leading cause of blindness, end stage renal disease, and non-traumatic 
amputation in Canadian adults18. In 2017 the IDF recommended that overweight and 
moderately obese subjects (BMI between 25-35) should consume a low calorie diet 
between 800-1200 calories per day and lose approximately 10 pounds regardless of 
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starting body weight. This recommendation was made for patients with type II diabetes 
mellitus (T2DM). As part of this recommendation based on current evidence in the 
literature, a recommendation was also made by IDF to consider bariatric surgery for 
people with T2DM and BMI between 30 and 35 when the metabolic response to regular 
treatment has been poor19. There have been many studies looking at bariatric surgery in 
patients with lower BMI (20-35). Much of these studies were performed initially in Asian 
populations where there is extremely high prevalence of T2DM in normal weight or 
overweight individuals20. Much of the earlier studies were retrospective in nature 
involving lower numbers of patients however as evidence mounted these procedures were 
being applied to a wider range of patients. Today there are many prospective and 
randomized controlled trials that have been performed on overweight and obese patients, 
which is the subject of this analysis. Our goal is to review the highest levels of evidence 
to establish whether bariatric surgery is safe and effective in this patient population.  
 
Chapter 2 - Literature review 
Introduction 
 The main goal of any surgical intervention is to provide a high level of efficacy 
while maintaining a favorable safety profile. Bariatric surgery has evolved over time and 
a preliminary review of the literature is important to ensure that the intervention in 
question is indeed safe and efficacious. It is also important to review the current literature 
with respect to our research question. Our objectives with respect to literature review are: 
(1) Review evidence for bariatric surgery in patients with morbid and class II obesity. (2) 
Explore evidence for bariatric surgery in overweight and class I obese patients 
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(moderately obese). (3) Review previous systematic reviews of patients who are 
moderately obese.  
 
2.1 Surgery for Morbid obesity  
Introduction 
 Initial data were presented with open gastric bypass, which had a very strong 
impact in morbidly obese patients. The 1980s saw the advent of laparoscopic surgery, 
which had dramatic effects on morbidity, mortality, length of stay in hospital, return to 
usual duties and overall faster recovery when compared to open surgery13. The 1990s saw 
the advent of newer somewhat novel procedures such as adjustable gastric banding 
(AGB) and sleeve gastrectomy. These procedures were shown to have favorable 
complication profiles while maintaining excellent excess weight loss and resolution of 
obesity related comorbidities in morbidly obese patients. Here we explore some of the 
evidence for bariatric surgery in morbidly obese and moderately obese subjects. The 
included studies were chosen to give broad representation of the evolution of bariatric 
surgery and because they are significant in their own right.  
 
Literature Review 
Mason et. al. 196910 
  Mason and colleagues developed the open technique of gastric bypass after the 
observation that patients undergoing total gastric resection remained thin. They describe 
the 90 percent gastric bypass operation for obesity given that about 90 percent of the 
stomach is excluded from digestion. Upper midline laparotomy incision is described in 
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detail and the left lobe of the liver is mobilized towards the patients’ right side. The 
stomach is then divided creating an approximately 10 percent by volume proximal gastric 
pouch. The ligament of treitz is divided and a short loop retro colic (behind and under the 
transverse colon) gastroenterostomy is performed. The mesocolon was secured to the 
gastric pouch by sutures to prevent internal hernia. The proximal gastric pouch is also 
sutured to the distal excluded portion of the stomach such to prevent torsion or 
intussusception of this segment. The idea was that this would help prevent gastric antral 
stasis and in turn help prevent development of jejunal ulcers.  This procedure was initially 
performed in dogs to assess safety and feasibility before being trialed in humans.  
 Over a 3-year period this procedure was performed on 24 patients who averaged 
222% of their estimated normal body weight. The range of preoperative weights was 
80.9kilograms (kg) to 295.5kg. The patients were equally divided by sex and ranged in 
age from 22-68 years. The authors looked specifically at patients with duodenal ulcers 
and proposed that the gastric bypass procedure would be an effective treatment. Total of 
10 patients had history of duodenal ulcer and all patients had relief of symptoms post 
operatively. There were two deaths in the cohort. One patient died from peritonitis in the 
absence of any suture line dehiscence and the other from pulmonary embolus. Several 
patients required monitoring in the intensive care unit with at least one patient requiring 
prolong ventilator support and tracheostomy. Two patients were readmitted 
postoperatively because of persistent vomiting and dehydration. Average weight loss 
during the follow up period was 39kg. Jejunal ulceration was initially a concern however 
only one patient developed jejunal ulcer. This was felt to be due to stasis in the excluded 
portion of the stomach and the patient underwent revisional surgery however this was not 
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detailed in the report. The authors conclude that gastric bypass can be recommended in 
the treatment of severe, intractable obesity with an acceptably low rate of jejunal 
ulceration. They go on to say that physically active, young or middle aged people 
weighing in the range of 200% of estimated normal body weight will respond better than 
others. Preoperative weight reduction may be required and Anesthesiologists experienced 
in care of obese patients and intensive care facilities will be necessary. Limitations of this 
study included non-randomized nature and of course much of the morbidity of the 
surgery associated with open technique. This was a landmark study and one of the first 
studies to explore the effects of gastric bypass on morbidly obese subjects, a surgical 
treatment that today remains one of the most commonly performed and efficacious 
procedures in this patient population.  
 
Pories et. al. 198221 
 Randomized controlled trial of 87 morbidly obese subjects to open gastric bypass 
versus gastric partition. Gastric bypass was performed by creating a small 50ml gastric 
pouch proximally using a non-cutting stapler that essentially occluded the stomach at this 
level. The small intestine was then brought through in a retro colic fashion and 
anastomosed to the gastric pouch using a hand-sewn technique. The size of the 
gastrojejunostomy was said to be standardized to 0.8cm by suturing over a number 18 
nasogastric tube. Gastric partition was completed in a similar fashion however instead of 
a gastrojejunostomy anastomosis the gastric pouch was sutured to the inferior portion of 
the stomach that had been divided creating a gastro-gastrostomy. This was done in a 
similar fashion via hand-sewn approach over number 18 nasogastric tube. Patients were 
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monitored in the intensive care unit for 24 hours and then on the wards for 3 days with 
nasogastric (NG) tube in situ until they passed flatus. At that point the NG tube was 
removed and patients were started on a fluid diet and slowly advanced based on 
symptoms. There was no statistically significant difference between the groups in terms 
of age, weight, sex, and incidence of DM and hypertension. Follow up was performed at 
3, 6, 9, 12 and 18 months. Gastric bypass patients had greater weight loss at each point in 
follow up which was statistically significant. This was sustained at all points and at 18 
months follow up the gastric bypass group had a mean weight 79.2kg. compared to the 
gastric partition group at 110.1kg. Both procedures had a positive effect on diabetes and 
hypertension with all but one patient with diabetes being normoglycemic postoperatively. 
Of patients with hypertension only 1 of 19 in the gastric partition group had persistent 
hypertension and 2 of 16 in the gastric bypass group remained hypertensive. 
Complications were equally distributed amongst the groups. The authors conclude that 
gastric bypass is a superior operation to gastric partition. This study highlighted the 
reproducibility and sustainability of the gastric bypass procedure. It also highlighted the 
dramatic effect on weight loss that bypassing the proximal gastrointestinal tract would 
provide and that pure restriction could not provide the same effect. This result would be 
reproduced in years to come.  
 
Wittgrove et. al. 199615 
 Early study looking at effectiveness of laparoscopic roux en y gastric bypass 
(LRYGB). Cohort study looking at 27 patients who underwent LRYGB. Patients were 
selected using criteria set out by NIH consensus panel. The technique of open RYGB has 
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been described previously.  Routine preoperative workup was completed and patients 
were operated via laparoscopic approach. Similar to technique described by Mason the 
stomach is completely divided creating small 15ml gastric pouch. Small bowel is divided 
and 75cm roux limb is brought in retro colic fashion and anastomosed to the gastric 
pouch using 21mm circular stapler. Standard enteroenterostomy is performed to complete 
the procedure. Upper gastrointestinal series was completed on first postoperative day 
using water-soluble contrast media and clear fluid diet was started on the same day. 
Average length of stay was 2.8 days. Complications were comparable to earlier studies 
with one anastomotic leak in this series. There was 1 intra abdominal abscess and 2 
patients had stenosis of the gastrojejunostomy requiring dilation.  Patients were followed 
up at 3, 6, 9, 12 and 18 months. Mean excess weight loss at 18 months was 80%. 
Hypertriglyceridemia, diabetes, stress incontinence, arthritis and sleep apnea were 
resolved in all patients post operatively. Gastroesophageal reflux persisted in 1 of 22 
patients and hypercholesterolemia in 2 of 14 patients. Patients were seen to have shorter 
hospital stay, earlier return to usual activities and superior cosmetic effect as compared to 
studies looking at open surgery. The authors conclude that LRYGB is a safe, effective 
treatment for morbid obesity and because of significant reduction in length of stay 
potentially cost effective. The advent of laparoscopic surgery had a major impact on the 
outcome of surgical patients and this was also seen in bariatric patients undergoing 
surgery. This study was one of the first reports to show that laparoscopic RYGB was safe 
in morbidly obese patients with a favorable side effect profile.  
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Dixon et. al. 200222 
 The 1990s and early 2000s saw further advancement in bariatric surgery as 
surgeons pushed to develop newer techniques that would decrease surgical morbidity and 
complications such as ulceration and internal hernias that were seen with gastric bypass. 
Dixon and colleagues published their data on laparoscopic adjustable gastric band 
(LAGB) for the treatment of morbid obesity. LAGB consists of a silicone elastomer with 
inflatable inner shell that is placed around the proximal stomach and secured using a 
buckle closure. The band is connected by tubing to an access port that is placed in the 
subcutaneous tissues anterior to the abdominal wall fascia. The port can then be accessed 
via syringe and the inner diameter of the band can be adjusted by injecting or 
withdrawing fluid as desired. This system was designed as an option for individuals who 
do not wish to have irreversible alteration to proximal gastrointestinal tract. This was a 
cohort study and 50 patients were included.  Laparoscopic surgery was achieved in 47 
while 3 patients had open approach for revisional surgery and band placement. Median 
hospital stay was 2 days. There were 2 patients with wound infections and 1 patient 
required postoperative respiratory support. All of these complications occurred in those 
partaking open surgery. While early postoperative outcomes are favorable with respect to 
complications, late issues such as prolapse of the stomach through the band (20%) and 
band erosion (6%) were seen not infrequently and most required operative intervention. 
At 1 year of follow up statistically significant changes were seen in fasting plasma 
glucose, hemoglobin A1c, fasting triglyceride, liver enzymes and need for oral 
hypoglycemics.  Mean excess weight loss at 1 year was 38+/-14%. There were also 
significant improvements in qualitative markers such as physical function, pain, general 
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health, and energy. The authors conclude that LAGB is an effective treatment for T2DM 
and obesity related comorbidities in morbidly obese patients. The effects with AGB are 
somewhat less robust than what is seen with other surgical procedures such as LREYGB 
however the short-term complication rate is favorable.  
 
Nocca et. al. 200716 
 Laparoscopic sleeve gastrectomy (LSG) has been described as stand alone 
bariatric procedure after it’s inception during duodenal switch procedure and has been 
widely adopted to morbidly obese patients. This is a multicenter prospective study. Over 
a 3-year period 163 patients underwent LSG by 5 different surgeons. Average body mass 
index (BMI) was 45.9 kg/m2. Surgery was standardized amongst all 5 surgeons. Left lobe 
of the liver was retracted anteriorly and the gastro colic ligament was divided and the 
bursa minor was entered using ultrasonic sheers. The dissection along the greater 
curvature started 10cm from the pylorus and progresses toward the diaphragm. 36french 
calibration tube was placed trans orally along the lesser curvature to perform a controlled 
vertical gastrectomy. The gastrectomy was completed using endoscopic linear stapler of 
appropriate cartridge and the staple line may have been buttressed with sutures or with 
absorbable material. The staple line was checked for leakage by injecting methylene blue 
through an orogastric tube. Suction drain was left in situ. All patients were optimized 
perioperatively in a standard fashion. Barium swallow was performed on postoperative 
day 2. Nasogastric tube was removed at this point and the patients were started on liquid 
diet.  
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There were no conversions to laparotomy in this group. LSG was primary 
procedure in most subjects however 22 persons were operated after failure of AGB. 
Perioperative complication rate was 7.4%. Patients were followed for total of 2 years post 
operatively. Excess weight loss (EWL) and BMI at 2 years were 61.5% and 31.6kg/m2. 
Weight regain was reported in 10 patients. This study is one of the first reports of sleeve 
gastrectomy as a primary bariatric procedure. The Authors conclude that sleeve 
gastrectomy is a safe and effective restrictive bariatric procedure to treat morbid obesity 
in select patients. They concede that weight regain, quality of life and evolution of 
morbidities due to obesity need to be evaluated in long term follow up.  
 
Summary 
 Surgical management of morbid obesity has evolved and today surgery remains 
one of the most efficacious long-term treatments for severe obesity14. Moreover, Surgery 
has been shown to provide effective, durable treatment for T2DM and other obesity 
related comorbidities such as hypertension, hypercholesterolemia, sleep apnea, and 
osteoarthritis. The advent of laparoscopy and other minimally invasive techniques has 
decreased the morbidity of these procedures substantially where the risk benefit profile 
weighs heavily in favor of surgery. The American Diabetes association recommends 
consideration of bariatric surgery for any patient with T2DM and BMI > 40 where 
hyperglycemia persists despite adequate medical and lifestyle intervention. In fact, a 
substantial amount of literature exists to show that surgery when compared to medical 
and lifestyle modifications provides superior glycemic control and reduction of 
cardiovascular risk factors in obese patients with T2DM14.  Surgery has also been shown 
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to be associated with long-term improvement in mortality23. I believe that the evidence 
weighs strongly in favor of bariatric surgery for obese individuals as highlighted by the 
previous studies. I believe that the true effect of these surgeries particularly with respect 
to patients with moderate obesity is largely unknown and will be the subject of much 
future research.  
 
2.2 Surgery for Moderate Obesity 
Introduction 
Over the years a multitude of data has arisen supporting the implementation of 
bariatric and metabolic surgery for patients with severe obesity (BMI > 35). The dramatic 
effect that has been seen with respect to T2DM has led investigators to consider whether 
surgery will be effective in patients with BMI < 35. Here we review some of the data 
regarding surgery in patients with BMI < 35. While this is not a comprehensive review 
we feel the following studies are representative of surgery in this patient population.  
 
Literature Review 
Noya et. al. 199824 
 Touted as being one of the first reports of metabolic surgery in patients with BMI 
< 35, Noya and colleagues performed biliopancreatic diversion (BPD) without gastric 
resection in 10 patients. Mean BMI was 33.2kg/m2. Mean age and weight were 52.1 years 
and 85.2kg respectively. 5 males and 5 females in total. All patients had 
hypercholesterolemia and hypertriglyceridemia for over 5 years. All patients had T2DM 
with two patients taking insulin and two others taking oral hypoglycemic agents. 
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Remaining patients were diet controlled. Duodenum was transected and along with the 
small bowel at a point 50cm proximal to the ileocecal valve. Small bowel was connected 
to the duodenum using biodegradable ring in 3 cases and hand sewn in 7. Postoperative 
course was described as uneventful with patients resuming diet on postoperative day 10-
12. All patients were discharged by postoperative day 15. Maximal follow up reported 
here was 12 months. All patients had cholesterol and triglyceride levels return to normal. 
9 patients had normal glycemic values with one patient who had been taking 70 units of 
insulin per day decreased to 35 units of insulin with discontinuation of oral medications 
for same. All patients were normotensive post operatively. Mean BMI decreased to 
30.5kg/m2. One patient suffered pulmonary embolus that responded to medical treatment. 
One patient required re operation to treat obstruction secondary to the biodegradable ring. 
Weight loss was described as moderate with 10-15kg reduction in body weight in the first 
month after surgery. The authors conclude that this modification of the original BPD 
procedure without gastric resection is effective in controlling lipid metabolism and 
T2DM in patients who are moderately obese. Given that the amount of weight loss seen 
with this approach is lower than would be expected with original BPD, the modification 
described here is not recommended for morbidly obese patients. Limitations of the study 
were small number of patients, retrospective nature and limited generalizability due to 
higher complication rates compared to other bariatric procedures. This study has been 
touted as being one of the first series of patients with moderate obesity to undergo 
bariatric surgery25.  
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DePaula et. al. 200826 
 Prospective study of 39 patients undergoing either ileal interposition with sleeve 
gastrectomy (ILSG) or ileal interposition with diverted sleeve gastrectomy (ILDSG).  The 
study population consisted of patients with BMI between 23.4-34.9 kg/m2 with mean 
BMI of 30.1kg/m2. Inclusion criteria also included type 2 diabetic patients whose disease 
had been diagnosed for at least 3 years, HbA1c > 7.5, stable weight defined as no 
significant change over previous 3 months, and evidence of stable treatment with oral 
hypoglycemic therapy or insulin for at least 12 months. Patients were not assigned 
randomly to either surgical group. Patients > 66 years old, previous major upper 
abdominal surgery, pregnancy, severe comorbidities, use of appetite suppressant, and 
presence of eating disorder or other endocrine disorder were all listed as exclusion 
criteria. IlSG started with division of the jejunum 50cm from the ligament of treitz. A 
100cm segment of ileum is then isolated by division about 50cm proximal to the ileocecal 
valve. This 100cm segment of ileum is then anastomosed to the proximal jejunum at the 
point previously transected. Ileal interposition is proposed to improve glucose 
metabolism by different mechanisms including up regulation of glucagon like 
polypeptide-1 (GLP-1) by early food contact with ileal mucosa. This in turn helps 
regulate early phase insulin secretion and maintaining glucose homeostasis. Sleeve 
gastrectomy is standard part of the procedure. The greater curvature of the stomach is 
devascularized using ultrasonic scalpel. 30french orogastric tube is placed to calibrate the 
sleeve along the lesser curvature. The gastric resection is started at the antrum and carried 
to the diaphragm using linear stapler. Staple line is over sewn. ILDSG combines ileal 
interposition as described above with diverted sleeve gastrectomy. Once the gastric 
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sleeve is created the dissection is carried beyond the pylorus and the proximal duodenum 
is divided using a linear stapler. The proximal duodenal mucosa along with the gastric 
remnant is then attached to the distal end of the jejunum divided proximally. The 
proximal jejunum that had been divided 50cm from the ligament of treitz is then 
anastomosed to the interposed ileum. ILSG was performed for 23 patients and ILDSG in 
16 patients. Median hospital stay was 4.3 days. Major complications including gastric 
leak and acute renal failure were experienced in 10.3% of patients. Minor complications 
including urinary tract infection and prolonged ileus were noted in 15.4% of patients. 
Total of 30 patients were followed for mean of 7 months (range 4-16 months). Significant 
improvements (p < 0.001) were seen in Hemoglobin A1c, fasting glucose, total 
cholesterol, and triglycerides (6.3 +/- 0.9 vs. 8.8 +/- 1.7; 116.7 +/- 33.1mg/dl vs. 210.7 +/- 
66.6mg.dl; 165.7 +/- 27.6mg/dl vs. 215.1 +/- 49.9mg/dl; and 131.3 +/- 80.2mg/dl vs. 
250.5 +/- 168.4mg/dl respectively). Mean percentage loss of initial weight was 22% with 
5.2% of patients having BMI below 20kg/m2.  
 The authors conclude that IlSG and ILDSG may be considered for treatment of 
metabolic syndrome and type 2 diabetes mellitus in non-morbidly obese subjects. A 
profound effect was seen with respect to glucose metabolism and dyslipidemia. Weight 
loss as a secondary measure was also dramatic. The limitations of the study are small 
number of patients, brevity of the follow up period and lack of relevant control groups. 
One must also consider the staggering complication rate with more than 10% of patients 
suffering major complications in the early postoperative period. This is not surprising 
given previous studies of the ileal interposition procedure in obese subjects that also 
reported high rates of complications that ultimately led to these surgeries being largely 
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abandoned in favor of other surgeries that have more favorable perioperative outcomes 
such as gastric bypass and sleeve gastrectomy.  
 
Serrot et. al. 20114 
 Much of the strongest evidence for bariatric surgery in morbidly obese subjects 
came from data on patients undergoing open gastric bypass and later laparoscopic roux en 
y gastric bypass (LRYGB). This led investigators to explore the effects of LRYGB on 
moderately obese subjects, hence much of the literature to date on this patient population 
comes from patients who underwent gastric bypass. Serrot and colleagues performed a 
retrospective review of their data in patients undergoing LRYGB. Inclusion criteria were 
patients with BMI < 35 and T2DM. Interestingly these patients would have had BMI > 35 
at some point in their life however at the time of surgery BMI was < 35. They also 
tracked patients undergoing routine medical management in their center and matched 
them to patients with similar BMI undergoing surgery. Patients underwent standard 
gastric bypass with 15-30ml gastric pouch and 75-150cm roux limb and 75-100cm 
biliopancreatic limb. Patients were followed up for a maximum period of 12 months. 
Patients in medical arm were followed similarly and had their medications adjusted by 
dedicated pharmacist and diabetic nurse. They also received counseling regarding 
nutrition, exercise and weight management. Total of 34 patients were included in the 
analysis. Participants at baseline were similar in almost every respect except the surgery 
group had higher proportion of females and higher HbA1c (13 vs. 6, P = 0.04; 8.2 vs. 7.0 
p = 0.04). Significant differences were seen with respect to weight loss. Surgical group 
had change in BMI from 34.6+/-0.8 kg/m2 to 25.8+/-2.5 kg/m2 compared to essentially no 
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change in the medical group from 34.1+/-1.0 kg/m2 to 34.3+/-2.1 kg/m2 ( p < 0.001). 
HbA1c decreased in the REYGB group from 8.2 +/-2.0 to 6.1+/-2.7 but did not change in 
the medical group (7.0+/-0.7 to 7.1+/-1.8 P < 0.001). Blood pressure and LDL cholesterol 
did not significantly change in either group. Fewer patients in the surgical group were 
taking medications for glycemic control at the end of the study with 71% of patients 
taking less medications at one year compared to 6% in the non-surgical group (p < 
0.001). Total readmission rate for the surgical group was 18%. At one year 2 patients had 
developed incisional hernias that required repair and 2 further patients developed 
marginal ulcers that were managed medically. No mortalities were reported in either 
group. Limitations of the study included the small numbers of patients and several 
differences that were present between the groups at baseline. Retrospective nature of the 
analysis was also identified as a limitation. The authors conclude that RYGB could be a 
safe and effective treatment in patients with moderate obesity, particularly in the setting 
of T2DM without risk of hypoglycemia.  
 
Lee et. al. 201127 
 Randomized controlled trial comparing moderately obese subjects undergoing 
gastric bypass versus sleeve gastrectomy (LSG). Patients were eligible if they were 
between 30-60 years of age and had BMI between 25-35 and had poorly controlled 
T2DM as defined as HbA1c > 7.5%. Patients were excluded if they had undergone 
previous bariatric procedure, drug or alcohol addiction, neoplasm or evidence of portal 
hypertension. Block randomization to either gastric bypass or LSG was performed with 
block size of 10. Randomization was performed in the operating room after 
	 25	
pneumoperitoneum was established. Sleeve gastrectomy was performed in standard 
fashion by resecting the greater curvature of the stomach from approximately 4cm 
proximal to the pylorus to the diaphragm using a stapler. Remnant stomach was 
approximately 2cm wide. Staple line was over sewn using running absorbable suture. For 
the gastric bypass group a long sleeved gastrectomy was created similarly and a loop 
gastroenterostomy was created with the small bowel approximately 120cm from the 
ligament of treitz. Postoperative care was standardized with patients being discharged on 
postoperative days 3-4. Primary endpoint of the study was glycemic control at 12 months 
post surgery. This was assessed as participants achieving remission of T2DM, defined as 
FPG < 126mg/dL and HbA1c values less than 6.5% without the use of oral 
hypoglycemics or insulin. Secondary outcome measures were weight, blood pressure, 
waist circumference and fasting lipids. Total of 60 patients were randomized with 30 
patients in each group. Mean BMI and age were 30.3 and 45 years respectively. Both 
study groups were demographically similar.  There were no deaths or major 
complications in each group. Surgical time was similar between groups and the mean 
hospital stay was 2.2 in the gastric bypass group and 2.1 days in the LSG group. Overall 
70% of patients experienced T2DM resolution after 12 months. This was significantly 
better in the gastric bypass group than the LSG group (93% vs. 47% p = 0.02). Gastric 
bypass patients also had better weight loss and significantly lower FPG, waist 
circumference, HbA1c and lipids at 6 and 12 months post operatively. This was perhaps 
the first randomized controlled trial comparing surgical interventions in patients with 
moderate obesity (BMI < 35). Although both surgical groups appeared to have excellent 
results with low rates of complications, the gastric bypass group appeared to be superior 
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in almost every aspect. Exclusion of the duodenum and proximal foregut has been 
hypothesized as an important component of metabolic surgery and has been put forth as 
an explanation of why traditionally bypass procedures can achieve rates of resolution of 
T2DM of > 80% while purely restrictive procedures typically result in about 50% 
resolution. The results of this study seem to support that hypothesis however one main 
limitation is the lack of hormone data in this study. Sleeve gastrectomy was initially 
touted as being purely restrictive procedure however proponents of this procedure will 
argue that removal of 80% of the stomach has metabolic effects beyond the restriction 
that occurs. The lack of hormonal data in this study makes any direct comparisons in this 
regard virtually impossible. The authors conclude that gastric bypass surgery is more 
effective than sleeve gastrectomy for the surgical treatment of T2DM and control of 
metabolic syndrome. They go on to add that duodenal exclusion plays an important role 
in the mechanism of diabetes mellitus remission.  
 
Zhu et. al. 201228 
 Prospective study of 30 Chinese T2DM patients with BMI < 35 who underwent 
LRYGB. Patients were excluded if they had history of open abdominal surgery, unstable 
psychiatric illness, alcohol or drug dependence, active helicobacter pylori infection or age 
> 65 years. Patients underwent thorough preoperative workup and had LRYGB 
performed under general anesthesia with 4 trocars. Standard technique of RYGB was 
performed. Mean operative time was 2.85h. Clear fluid and liquid diets were started on 
the 4th and 7th postoperative day respectively. Solids were started in the 4th postoperative 
week. Patients were followed up at 3, 6 and 12 months after surgery. Of the 30 patients 
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who participated there were 22 males and 8 females. Mean age was 48.16. Mean FPG 
was 8.01 mmol/l and HbA1c was 8.02%. No significant surgery associated outcomes 
were identified except one patient who developed gastroparesis and had prolonged 
hospital stay. No mortalities were noted. There were significant changes noted in BMI 
(28.5+/-1.85 vs. 32.20 +/-1.56, P = 0.015), Waist – hip ratio (0.83+/-0.51 vs. 0.96+/-0.07, 
P = 0.010), Fasting plasma glucose (5.95+/-1.10mmol/L vs. 8.01+/-2.08mmol/L, P = 
0.040), and HbA1c (5.59+/-1.02 vs. 8.02+/-1.77 P = 0.049). The authors discuss that 
Chinese patients with T2DM typically have BMI < 35 and central obesity. Bypassing the 
proximal GI tract seems to have a dramatic effect on glucose metabolism independent of 
weight loss although there was a significant change in BMI post operatively in this study. 
Limitation of this study is the relatively short term follow up of 12 months. The authors 
conclude that LRYGB is a safe and effective treatment for T2DM in non-morbidly obese 
patients with potential for complete remission of the disease. They also concede that 
further studies will be necessary to establish long-term efficacy.   
 
Summary 
 Early results of bariatric surgery in moderately obese patients are promising. 
While early studies utilizing ileal interposition type procedure revealed dramatic effect on 
weight loss, glucose metabolism and other obesity related comorbidities, relatively high 
perioperative complication rate limits the transferability of these results. Further studies 
utilizing gastric bypass, sleeve gastrectomy and adjustable gastric banding via 
laparoscopy have shown promising data with a more favorable safety profile. While the 
early results are promising, majority of the data thus far has been retrospective in nature 
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and most studies involve relatively low numbers of patients.  These limitations inherently 
weaken any conclusions drawn from this data. This opened the door for further 
prospective studies, randomized controlled trials and meta analyses.  
  
2.3 Surgery for Moderate Obesity - Previous Meta Analyses 
Introduction 
Systematic reviews and Meta analyses are some of the highest levels of scientific 
evidence that we have to base clinical practice. Outcomes from a meta-analysis may 
include a more precise estimate of the effect of treatment or risk factor for disease, or 
other outcomes, than any individual study contributing to the pooled analysis29. 
These analyses have some inherent biases such as selection bias, however the 
information provided is of the utmost importance in answering clinical questions. 
Combining several studies to perform review and if applicable, meta analysis has several 
clear advantages. Single studies may have unique characteristics that may limit the 
generalizability and combining studies can also increase the sample size and produce 
more precise estimates of the effect size. Many clinicians rarely have the time or 
resources to critically appraise the literature relevant to a particular clinical question and 
most systematic reviews will focus on a narrow, clearly defined topic that will allow the 
inclusion of all relevant articles29. Here we review some of the previous systematic 
reviews that have been performed relevant to our topic. While this review is not 
comprehensive, we feel that the chosen studies are representative of previous systematic 
reviews and meta analyses performed on patients with BMI < 35 undergoing bariatric 
surgery.  
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Literature Review 
Fried et. al 201025 
Integrated review of patients operated with mean BMI < 35. Inclusion criteria 
were any form of bariatric/metabolic surgery in human subjects where mean BMI < 35. 
Primary outcome measure were data on treatment of type 2 diabetes mellitus. Major 
databases were employed such as MEDLINE, current contents, science citation index and 
Cochrane library. Total of 16 studies were included with total of 343 patients undergoing 
8 different surgical procedures. Procedures were categorized as either restrictive, 
malabsorptive, or combination of restrictive/malabsorptive. 66% of patients were female 
and mean age at baseline was 46.2 years. Study design ranged from case report of 2 
patients in larger prospective study of 50 patients, to retrospective case series and 
matched controlled trials. 11 of the studies were prospectively performed. 4 studies 
revealed statistically significant changes in BMI, 6 for fasting plasma glucose, and 6 for 
hemoglobin A1c. Overall the mortality in the entire analysis was 0.29%. Complication 
rate was low at 4% while one study reported an overall rate of major complications of 
10.3%. The authors found that all categories of bariatric procedures were effective, by 
varying definitions of resolution, in reducing and in most cases resolving type 2 diabetes 
mellitus. The authors also noted that subset of patients with BMI 25.0-29.9 had lower 
percentage reduction in clinical and laboratory measures of T2DM compared to patients 
with BMI 30-35. Limitations of the review were the small numbers of patients in each of 
the studies and the fact that most of the studies were observational in nature. There were 
also a large proportion of retrospective studies included in this review. Reporting of 
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measures of T2DM was also highly varied with incomplete data in many studies. The 
authors conclude that bariatric surgery can be a safe and efficacious treatment for T2DM 
in non-morbidly obese population. They concede that the level of evidence based on 
these studies is weak and that their data represents preliminary evidence and that further 
research will be required to institute change in the inclusion criteria for patients 
undergoing bariatric and metabolic surgery.  
 
Meijer et. al. 201130 
 Systematic review looking specifically at reversal of T2DM in patients 
undergoing LRYGB or AGB. Typical PubMed search was performed using usual MESH 
terms. Other databases were not included in this review. Results with respect to 
improvement in T2DM and reversal of T2DM were not clearly defined. One study 
reported on patients requiring insulin and patients who were able to completely 
discontinue their insulin were said to have reversal of T2DM and others that were able to 
decrease their daily insulin use were said to have improvement in T2DM. Studies 
included patients with BMI < 35. Total of 9 studies were included in the analysis. All but 
2 studies were retrospective case series with one RCT comparing AGB to medical 
therapy and one observational prospective study comparing AGB and LRYGB and as 
well vertical banded gastroplasty, a purely restrictive procedure that has been largely 
abandoned because of high complication and failure rates6.  Reversal rates of T2DM 
reported in the included studies ranged from 43% of subjects to as high as 87%. 
Improvement was seen anywhere from 91-100% of subjects. More dramatic rates of 
resolution and improvement of T2DM were seen with LRYGB compared to other 
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surgical groups. Authors also noted improvement in hypertension in up to 80% of 
patients. Improvements in hypercholesterolemia, hypertriglyceridemia, cardiac function 
and obstructive sleep apnea were also noted to occur however less frequently. Limitations 
of the study were small numbers of patients and retrospective nature of the included 
studies. The lack of standardization of reporting, especially with respect to T2DM 
endpoints also creates heterogeneity in the data. This makes further analysis impossible 
beyond a descriptive analysis and in turn will make the results less generalizable. With 
respect to current review of patients with BMI < 35, these patients represented a lower 
proportion of the total number of patients studied. The authors conclude that bariatric 
surgery, especially LRYGB, leads to reversal of, or improvement in T2DM and should be 
considered in patients with poorly controlled T2DM and a BMI greater than 35. They 
also conclude that similar results have been shown in patients with BMI < 35 however 
this remains controversial and would require further study.  
 
Adegbola et. al. 201331 
 Systematic review of patients with BMI < 35 undergoing AGB. Articles published 
after 1990 and in the English literature were reviewed. Patients undergoing AGB with 
BMI < 35 were included. All procedures were performed laparoscopically unless 
otherwise specified. Medline and Embase databases were searched using standard MeSH 
terms. Appropriate reference lists and bibliographies of selected articles were also 
searched for relevant articles. Patient characteristics including BMI, comorbidities, 
duration of follow up and endpoints including complications were included. 6 studies 
ultimately met the inclusion criteria. Of these, 5 were retrospective and 1 RCT was 
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included. Weight loss was reported in 5 of the 6 studies. 85% of patients were followed 
up with mean percentage excess weight loss (%EWL) ranging from 52.5+/-13.2 to 
78.6+/-9.4 and 57.6+/-29.3 to 87.2+/-9.5 at one and two years postoperatively 
respectively. At 5 years post operatively 72.4% of patients were followed up 
appropriately with %EWL of 71.9+/-10.7. With respect to obesity related comorbidities 
the data that was collected was somewhat heterogeneous. One study reported 89.1% of 
patients free of comorbidities at 1 year of follow up. Another study reported resolution of 
comorbidities in “most” patients. Resolution of metabolic syndrome was reported in 
93.3% of patients in another study. One study did not report on resolution of 
comorbidities. Mortality ranged from 0-1% while other complications including wound 
infection, band slippage/migration, band erosion and port leaks were reported anywhere 
from 0-5.2%.  
Limitations of this study include small number of studies included, short to 
medium term follow up, and exclusion of non-English language publications. The 
heterogeneous and vague nature of which obesity related comorbidities are evaluated also 
makes any firm conclusion in this regard difficult to make. The authors conclude that 
from the limited data available LAGB is well tolerated and effective with good short-term 
outcomes in obese patients with BMI < 35kg/m2. They also conclude that there appears 
to be a favorable impact on obesity related comorbidities however there remains a paucity 
of data on this group of patients and long term outcomes need to be further evaluated.  
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Rao et. al. 201532 
 Systematic review and meta analysis of patients undergoing laparoscopic roux en 
y gastric bypass (LRYGB). Other surgery types were excluded from this review. 
Inclusion criteria were patients who underwent LRYGB and had BMI < 35kg/m2 and had 
T2DM. Embase, Ovid, PubMed, Cochrane and China national knowledge infrastructure 
databases were searched. Relevant journals including obesity surgery and surgical 
endoscopy were also reviewed. Where datasets were incomplete study authors were 
contacted however no further information was obtained. Total of 9 studies met the 
inclusion criteria and were included in the review. All studies included patients 
undergoing LRYGB however one study also included patients who underwent mini 
gastric bypass, a variation on LRYGB. The authors felt this was appropriate given likely 
similar mechanism of action of the procedure. Follow up ranged from 1-7years. 6 of the 
studies included were prospective. Complete remission of T2DM was defined as HbA1c 
< 6. Partial remission of T2DM was defined as HbA1c between 6-7 and improvement 
was defined as HbA1c > 7. BMI was significantly lower in the postoperative group (p < 
0.00001, WMD -7.42, 95% CI -8.87 to -5.97). Values for glucose and HbA1c were also 
lower postoperatively (glucose p < 0.00001, WMD -59.87, 95% CI -67.74 to -52.01; 
HbA1c p < 0.00001, WMD -2.76, 95% CI -3.41 to -2.11). Funnel plot was symmetrical 
indicating no significant bias in this analysis. No deaths were reported in any of the trials 
with complication rates varying from 6.7-25.9%. The authors conclude that LREYGB 
can offer a substantial improvement and cure of T2DM for many patients although in this 
analysis not all patients achieved a complete remission (HbA1c < 6). They offer that 
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further clinical studies with larger sample sizes and longer follow up will help elucidate 
this issue.  
 
Muller-Stitch et. al. 201533 
 Systematic review and meta analysis of patients undergoing multiple surgical 
types in population with BMI < 35kg/m2. Medline, Embase and Cochrane databases were 
searched using key word algorithm. Studies evaluating metabolic surgery effect on 
T2DM in patients with BMI < 35kg/m22. Studies were also included if mean BMI of 
treatment group was < 40kg/m2. Abstracts were reviewed and full text review was 
performed for studies meeting the inclusion criteria. Further cross referencing was carried 
out for all included studies. T2DM remission was primary endpoint. This was defined as 
achievement of HbA1c of < 7 and fasting plasma glucose of < 7.2mmol/L and 
discontinuation of diabetic medications. It is noteworthy that studies included in this 
analysis had different cutoffs to define remission of T2DM. The study authors state that 
this was accounted for in their analysis. Secondary outcome measures were HbA1c 
levels, BMI, presence of hypertension and dyslipidemia. Total of 13 studies met the 
inclusion criteria and were included in the analysis. There were 7 randomized controlled 
trials and 6 observational cohort trials included comprising a total of 818 diabetic 
patients. Follow up ranged from 12-36 months. Remission rates of T2DM were 
significantly higher in the surgery group compared to medical treatment (OR 14.1, 95% 
CI 6.7-29.9, P < 0.001).  Glycemic control was significantly better in the surgical group 
(OR 8.0; 95% CI 4.2-15.2, P < 0.001). Using trim and fill method to adjust for potential 
publication bias this effect the effect on glycemic control remained strong (OR 7.2; 95% 
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CI 5.0-1-.3, P < 0.001). HbA1C values were lower in the surgical group (MD -1.4% CI -
1.8% to -0.9%, P < 0.001). Similar results were seen for body mass index, arterial 
hypertension and dyslipidemia (MD -5.5kg/m2, 95% CI -6.7 to -4.3kg/m2, P < 0.001; OR 
0.25, 95% CI 0.12 – 0.50, P < 0.001; OR 0.21, 95% CI 0.10 – 0.44, P < 0.001).  Moderate 
heterogeneity was seen with respect to hypertension with I2 = 64%, P =0.010. Sensitivity 
network meta analyses were performed to compare treatment effects across different 
surgical procedures. AGB, biliopancreatic diversion (BPD), LSG, and LRYGB were all 
proven to be significantly effective for T2DM remission. No significant heterogeneity 
was observed. Similar result was seen for glycemic control although LSG failed to reach 
level of significance. Analysis of HbA1c levels was compromised by relevant 
heterogeneity (Q = 72.2, I2 = 86%, P < 0.001). Serum HbA1c levels were significantly 
decreased after BPD, LSG, LRYGB but not by AGB. This study was one of the first to 
explore T2DM control in non-severely obese patients undergoing surgery (BMI < 35). 
Limitations included the heterogeneity in which T2DM remission was defined as well as 
other outcome parameters. This study clearly demonstrated the superior effect of surgery 
compared to medical therapy on T2DM and other obesity related comorbidities in 
patients with BMI < 35.  Because of a paucity of studies looking at this patient population 
the authors included studies where patients with BMI between 35 and 40 were included 
which also make any conclusions drawn from this analysis somewhat questionable and 
limits the generalizability. The authors concede this point however their conclusion was 
that surgery should be offered to non severely obese patients with T2DM and other 
elements of the metabolic syndrome. They also conclude that longer follow up and well 
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designed RCTs with standardized definitions of T2DM remission and glycemic control 
will be helpful to further explore surgery in this patient population.  
 
Summary 
 Bariatric and metabolic surgery for moderately obese patients is a relatively new 
area of investigation however the early results seem very promising. Much of the data 
had been extrapolated from morbidly obese subjects however more studies are being 
completed and the relative effectiveness of surgery for these patients is becoming clearer. 
Previous studies and meta analyses have shown very strong results however there are 
some limitations within these studies. Firstly, most studies to date have been retrospective 
in nature that brings inherent limitations such as a high risk of bias due to use of 
inappropriate control groups34. Lack of prospective and randomized data leaves the 
validity of these results in question. Secondly, most studies look primarily at T2DM and 
glucose metabolism as this seems to be highly prevalent not only in morbidly obese 
patients but also patients who are overweight or moderately obese. The effectiveness of 
bariatric and metabolic surgery on T2DM in this patient population seems to be well 
established however the treatment of other obesity related comorbidities such as 
hypertension and hypercholesterolemia seems to be less well defined. Minimal 
information regarding perioperative complications and lack of longterm follow up are 
also limitations of previous studies. Obesity related comorbidities are common even in 
moderately obese patients and the effectiveness of surgery on these factors remains 
largely in question. The results of previous meta analyses provide valuable information 
with regards to surgery in patients with moderate obesity however many studies which 
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were included in these analyses included patients with BMI > 35. This limits the 
generalizability of the results to moderately obese patients. Another important factor is 
that previous meta analyses have not included any randomized trials comparing surgical 
groups. As we have seen from the literature there are many bariatric and metabolic 
procedures that have been, and are being performed for obesity. Without any direct 
comparison it is extremely difficult to determine which procedure, if any will have better 
efficacy and safety for morbidly obese subjects. Meta-analysis is a quantitative, formal, 
epidemiological study design used to systematically assess previous research studies to 
derive conclusions about that body of research. Based on the key points highlighted 
above we felt that a meta analysis using the highest level of evidence available in patients 
with BMI < 35 would be necessary to fully answer our research question and to achieve 
our objectives which are: (1) To determine the efficacy and safety of bariatric surgery in 
patients with a BMI < 35 kg/m2 (2) To determine whether one surgical procedure will be 
superior in this patient population. (3) To fully explore the effect of surgery on less well 
studied obesity related comorbidities such as sleep apnea and osteoarthritis in patients 
with BMI < 35. 
 
Chapter 3 – Methods 
3.1 – PRISMA Statement 
 This systematic review and meta analysis was constructed according to the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines 
(PRISMA). These guidelines consist of a 27 point checklist that includes items deemed 
essential for transparent reporting of a systematic review. These guidelines were 
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developed in 2005 by a group of experts to ensure transparent reporting and expanded on 
previous guidelines developed in 1996 that led to the development of the Quality Of 
Reporting Of Meta-analyses statement (QUORUM) that came from the realization that 
key information was often omitted in systematic reviews diminishing their usefulness35.  
 
3.2 Protocol 
 Prior to beginning the study a detailed protocol was developed by the initial 
research team including members from Memorial University and The University of 
Ottawa (see co authorship statement). The protocol included primary area of interest, and 
how the data would be collected and analyzed. Once the protocol was finalized it was 
submitted to the Memorial University Department of Research and Graduate Studies as 
part of the final application. The details of the protocol will be discussed in the following 
sections. The protocol was not published or registered prior to commencement of the 
study.  
 
3.3 PICOS 
P – Patients with BMI < 35 undergoing bariatric surgery.  
I - Either Roux-en-Y gastric bypass, sleeve gastrectomy, or adjustable gastric band. 
C - Medical therapy or in case of comparison between surgical groups LREYGB would 
be considered experimental group. 
O - Primary outcome was fasting plasma glucose (FPG). Secondary outcomes were 
obesity related comorbidities, quality of life, mortality.  
S - Prospective studies including cohort studies and randomized controlled trials.  
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3.4 Eligibility criteria 
 We only included studies that were prospective in nature including randomized 
controlled trials, prospective cohort studies and case control studies where data were 
collected prospectively. Presence of a control group was not a prerequisite for inclusion. 
This has not been done in previous systematic reviews and meta analyses. Studies from 
English language literature were included along with studies that were specific to patients 
with BMI < 35. We also did not place any limits on language and felt that any relevant 
studies that were not printed in English would be translated and included in our study. 
While there are many procedures described for obesity and related comorbidities, we 
included only data on patients undergoing laparoscopic surgery, as this has become the 
standard of care for many abdominal procedures. We also felt that to create 
generalizability we would limit our review to patients who underwent adjustable gastric 
band procedure, gastric bypass, and sleeve gastrectomy. These three procedures are by far 
the most commonly performed procedures throughout the world and have proven safety 
profiles and have been shown to be efficacious. We excluded other procedures such as 
biliopancreatic diversion and duodenal switch as in some series these procedures have 
been shown to be associated with 2% risk of mortality, which we felt was unacceptably 
high to be translated to a patient population of moderately obese individuals until further 
data becomes available5. This decision was made on the basis of the current state of 
bariatric surgery throughout the world and expert opinion from our committee members.  
 Studies were excluded if they were retrospective in nature or if they included any 
patients who had BMI > 35. We also excluded studies where data was insufficient to 
complete any meaningful analysis. The analysis was limited to adult patients as the 
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implementation of bariatric surgery in the pediatric population is controversial and adds 
another confounding variable, which we felt would skew the results.  
 Studies were assessed for level of bias and this is detailed in section 3.10. Non 
randomized studies that were assessed critical level of bias and randomized studies that 
were assessed high level of bias were excluded from the analysis.  
 
3.5 Information sources 
 Electronic databases were searched using our pre specified protocol. Main 
databases included PubMed, EMBASE, Cochrane, and CINAHL. Relevant abstracts were 
collected and reviewed to ensure all relevant studies were captured. The search was 
started on may 1, 2012 and the final search was performed on December 1, 2017. 
PubMed is one of the most comprehensive databases throughout the world and we felt 
that this would be one of the most important databases to include. EMBASE has a special 
focus on drugs and pharmacology and we felt this would be especially relevant given that 
bariatric surgery is often compared to medical therapy especially with respect to T2DM. 
Cochrane database of systematic reviews and meta analyses is generally accepted as one 
of the most comprehensive databases of systematic reviews and was therefore included in 
the search. CINAHL was included to include all relevant allied health studies.  
 
3.6 – Search 
 We felt it was important to encompass all relevant studies and as such started with 
a very broad search. Of course we wanted to capture all relevant articles without having 
an excess of extraneous citations to review which would make the process much more 
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difficult and time consuming. Our main focus was patients with BMI < 35 so part of our 
search strategy was to ensure that all abbreviations and written forms were captured. For 
example we used the search terms “bmi < 35”,  “body mass index < 35”, “body mass 
index less than 35”, etc. This strategy was also applied to other aspects of our search such 
as for gastric bypass where many abbreviations and variations on how the procedure is 
labeled are used in the literature. We used this strategy for each of the databases that were 
searched. For a complete list of search terms see appendix 5. We wanted to evaluate 
whether our search strategy would be too broad or too narrow and to do this we used our 
search strategy first in MEDLINE and reviewed the first 100 citations that were listed. 
These were reviewed and it was felt that approximately 20% of these citations would be 
potentially relevant to our topic of interest. Based on expert opinion within our group 
(JM) it was felt that this search strategy would be sufficiently broad to capture all relevant 
citations while sufficiently narrow such that the amount of time to review these citations 
would not be excessive.  
 
3.7 – Study Selection 
 All relevant citations were reviewed in an unblinded standardized manner by two 
independent reviewers (CS and DT). Any articles in question were reviewed by an 
independent third reviewer (PC). To ensure transparency amongst reviewers data on each 
of the relevant citations were extracted and placed in an excel spreadsheet so that it could 
be examined by all of the reviewers. All reviewers were physicians associated with 
Eastern Health and Memorial University. Any disagreement was resolved by consensus 
between all three reviewers. In general we felt that inter-rater agreement was excellent. 
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Ultimately there were 92 articles that were felt to be potentially relevant and upon initial 
review there was only disagreement regarding 4 of these citations (4.3%).  
 
3.8 – Data Collection Process 
 As a guide we used the Cochrane Consumers and Communication Review 
Group’s data extraction template to ensure all relevant data were extracted 
appropriately36. For ease of data extraction and translation to statistical software, initial 
data extracted was input into a Microsoft Excel file, which could then be easily modified 
as appropriate. Only citations where complete consensus between all three reviewers was 
reached were reviewed in detail. Data extraction and compilation was done by two 
primary researchers (CS and DT) and where disagreements occurred it was planned that a 
third author (PC) would review the data and consensus would be used to resolve such 
disagreements.  Where data sets were felt to be incomplete we contacted study authors 
directly via email to inquire as to whether any further data could be supplied for the 
analysis. Of the articles included in the study, four of these articles were felt to have 
incomplete data. Of the four study authors who were contacted three of these responded 
promptly however unfortunately they were unable to provide us with any further data or 
clarification. We were careful to exclude any duplicate reports from the data collection 
process.  
3.9 – Data Items 
 Information was extracted from each included study on (1) characteristics of study 
participants (including, surgery type, duration of follow up and number of participants); 
(2) Primary outcome measure FPG (which was converted to mmol/l when this variable 
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was given in different units); (3) Secondary outcome measures HbA1c, body weight, 
BMI, waist circumference, hypertension, dyslipidemia, and other obesity related 
comorbidities including osteoarthritis, obstructive sleep apnea, infertility, 
gastroesophageal reflux and venous stasis. For categorical variables data was converted 
to standard units. Where continuous variables were analyzed, we collected mean and 
standard deviation for study groups and control groups and these were identified 
appropriately. For cases where standard deviation was not given we used the standard 
formula using range divided by four to provide an accurate estimate of standard deviation 
to ensure that our statistical analysis could be complete.  
 
 
3.10 - Risk of Bias In Individual Studies 
 As per Cochrane and PRISMA guidelines a risk of bias assessment was 
performed for each study37. For non-randomized studies we used the Risk of Bias in Non 
Randomized Studies of Interventions (ROBINS-I) tool. Studies were analyzed and graded 
based on a number of variables including: confounding variables, selection of study 
participants, classification of interventions, deviations from intended interventions, 
missing data, measurement of outcomes, and selection of the reported result. Level of 
bias assigned overall was based on the most serious levels of bias that was given using 
the signaling questions. Once each individual study was graded it was then placed into 
one of the following four categories: 
1. Low risk of bias – The study is comparable to a well designed randomized 
controlled trial.  
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2. Moderate risk of bias – The study is significant but not comparable to well 
designed RCT.  
3. Serious risk of bias – The study has some significant problems.  
4. Critical risk of bias – The study is too problematic and should not be 
included in the analysis.  
For non randomized studies this tool was applied and any studies deemed to have critical 
risk of bias were excluded.  
For randomized controlled trials we used the Risk of Bias (ROB) 2.0 tool for 
individually randomized parallel group trials. The two scoring systems are similar,  
however with the ROB 2.0 tool signaling questions could also be answered with ‘not 
included’ if there were insufficient data in the study to sufficiently answer the questions. 
Once the studies were graded they were then assigned to one of the following levels of 
risk of bias:  
1. Low risk of bias – The study is judged to be at low risk of bias for all 
domains. 
2. Some concerns – The study is judged to be at some concerns in at least one 
domain. 
3. High risk of bias – The study is judged to be at high risk of bias in at least 
one domain or to have some concerns for multiple domains.  
For randomized controlled trials that were being considered for the study, those with high 
risk of bias judgments were excluded. If there was no information available for either 
randomized or non randomized studies on which to make a judgment these were also 
excluded.  
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3.11 – Summary Measures 
 Meta analysis was planned to be performed using weighted mean difference for 
continuous outcomes with 95% confidence interval and p < 0.05. Means were weighted 
according to inverse variance method. Negative mean difference was indicative of 
positive associative effect with experimental variable.  For categorical variables we used 
the Cochrane –maentel- hantzel method with 95% confidence interval to calculate the 
odds ratio (OR). Odds ratio less than 1 was indicative of association of individual 
variable with intervention in question. Unless otherwise specified a p value of < 0.05 was 
considered significant. Odds ratios are often reported in the literature as a measure of 
association between exposure and outcome. This statistical method does have some 
disadvantages. For example, in the event that the outcome measure is common in a 
research study (>10% when compared to the control group) the OR may overestimate the 
risk ratio or relative risk, which may be more intuitively understood as a measure of 
association. Risk ratios (RR) can only be calculated for cohort studies, which makes this 
statistic less versatile38. In our study we included results from cohort studies, randomized 
controlled trials and case control studies, which meant OR was a more practical statistic 
to analyze the data. This would ensure that the analysis of our results would be more 
homogenous.  
 
3.12 – Synthesis of Results       
 Statistical analysis and graphical representation was completed using R version 
3.3.1 statistical software using random effects model. We used forest plots to graphically 
display the overall results. Subgroup analysis was performed by looking at each surgery 
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type separately and by comparing randomized data between surgery groups. We used I2 
statistic as a measure of heterogeneity. This method is generally considered superior to 
Cochrane Q statistic, which has been shown to be poor at detecting true heterogeneity 
among studies as significant39 .  
 Given that we are exploring surgical interventions and due to the nature of the 
studies we chose random effects model for the meta analysis. As opposed to fixed effects 
model, this technique relies on the assumption that treatment effect across studies will be 
variable38. With differences in surgical technique, etc. we felt that this would be most 
appropriate for our analysis.  
 
3.13 – Risk of Bias Within Studies 
 Risk of bias assessment was completed using the risk of bias in non randomized 
studies instrument (ROBINS-I) as per PRISMA and Cochrane guidelines. Similarly for 
RCTs we used the risk of bias tool (ROB 2.0) for individually randomized parallel group 
trials again as per Cochrane and PRISMA. For each of the signaling questions each study 
was given an assessment of bias for that question and ultimately a final judgment 
regarding bias that was essentially the highest level of bias assigned during each of the 
signaling question assessments. Kakoulidis et. al40 was excluded at this stage given it had 
been assigned critical level of bias as outlined previously. Data from this study was 
excluded from meta analysis and included only for descriptive purposes.  
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3.14 – Risk of Bias Across Studies 
 We used funnel plots to represent publication bias. Funnel plot is a simple scatter 
plot of the intervention effect estimates of individual studies against some measure of 
each studies size or precision. Generally the effect estimates will be plotted on the 
horizontal scale and the measure of study size on the vertical axis. The precision of the 
estimated intervention effect increases as the size of the study increases. Effect estimates 
from small studies will therefore scatter more widely at the bottom of the graph with the 
spread narrowing among larger studies. In the absence of bias the plot should 
approximately resemble a symmetrical inverted funnel. The presence of bias will lead to 
an asymmetrical appearance of the funnel plot. The more pronounced the asymmetry the 
more likely it is that the amount of bias will be substantial. The statistical power of a 
study is determined by factors in addition to sample size such as the number of 
participants experiencing the event for dichotomous outcomes and the standard deviation 
of responses for continuous outcomes. In other words there are more factors beyond 
strictly sample size that will determine the power of an individual study. Because of this 
it is usually recommended to use the standard error of the intervention effect estimate 
rather than sample size to create the funnel plot. Here we used the effect on FPG as this 
was our primary outcome variable and because the majority of the studies included 
reported this information in an accurate fashion37.  
 
3.15 – Additional Analysis 
 We wanted to assess whether bariatric surgery would be effective for moderately 
obese individuals. This would include assessment of weight loss or change in BMI and 
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also whether it would be effective in resolution of obesity related comorbidities in this 
patient population. We also wanted to assess whether the treatment effect would be 
consistent between different procedure types which lead to further sub group analysis 
based on our literature review. An important question was also whether one surgical 
procedure would be superior to another. On this basis we aimed to answer the following 
questions: 
 1) Is bariatric or metabolic surgery safe and effective for weight loss and 
resolution of obesity related comorbidities in patients with BMI < 35? 
 (2) Are the effects consistent between surgical procedures? 
(3) Is there one surgical procedure that is superior in this patient population? 
 
Chapter 4 – Results 
4.1 – Study Selection 
Review of Cochrane, Medline, Embase and CINAHL databases yielded total of 
1966 potentially relevant citations. All of the potentially relevant articles returned were 
from English language literature. To ensure that our search strategy was appropriate we 
reviewed 100 of these citations to see what percentage were potentially relevant. Once 
these were reviewed we found that 20% of these references were potentially valid. Based 
on expert opinion (JM) we felt that this would be appropriate and indicative that our 
search strategy was sufficiently broad to capture all relevant articles but also focused 
enough as to minimize the amount of time spent reviewing non relevant articles. Once we 
removed duplicates and screened for articles that were clearly not relevant based on 
review of the abstracts we were left with 546 potentially relevant articles. These were 
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further screened which left us with 92 articles for full text review and application of 
inclusion/exclusion criteria. 8 studies were excluded because of retrospective nature of 
study design. 22 were excluded because patients with BMI > 35 were also included. 13 
were excluded because outcome measures of interest were not reported. Remaining 
articles were excluded for various reasons including: lack of control group, systematic 
review, alternative surgical procedure or variation included, etc. There were total of 4 
articles on which the reviewers disagreed regarding inclusion/exclusion. A third 
independent reviewer reviewed these and consensus was reached on whether they should 
be included. This left us with a total of 14 articles to be included in the final systematic 
review and meta analysis. During the assessment of bias one study was assessed critical 
risk of bias and was therefore excluded from the analysis. Kakoulidis et. al was ultimately 
excluded because of lack of control for confounding variables, inconsistent reporting of 
data and because ultimately this was a subgroup analysis of a larger study. This left 13 
articles to be included in the final synthesis (see figure 4.1 - PRISMA diagram). 
 
4.2 – Study Characteristics 
 Total of 505 patients were included in the analysis. All studies were published in 
English language literature. There were total of 4RCTs and 9 prospective cohort studies. 
Of the 4 randomized controlled trials, 2 compared LSG to LRYGB. One compared LSG 
to medical therapy and one compared AGB to medical therapy. Of the 9 cohort studies 6 
involved patients undergoing LRYGB. One study looked at patients undergoing LSG and 
2 involved patients who received AGB. Control group for all included prospective studies 
was pre-surgical group. To date this is the only body of work utilizing prospective data 
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and limited to patients with BMI < 35. Follow up ranged from 1 to 5 years. All included 
studies were single centered. 10 studies gave complete data on our primary outcome 
measure of FPG, 9 studies included data on HbA1c. With respect to glucose metabolism 
remaining studies reported change in medications and resolution of diabetes, etc. 11 
studies gave data on BMI. 6 studies gave accurate information regarding hypertension 
and 4 reported on waist circumference. 5 studies gave data regarding dyslipidemia and 
body weight. Some studies reported on other variables including: osteoarthritis, 
infertility, insulin homeostasis, venous stasis, and urinary stress incontinence however the 
data was too heterogeneous and inconsistent to provide any meaningful analysis. See 
tables section for complete summaries of included studies and table 22 for overall 
summary of included studies.  
 
4.3 – Results of Individual Studies and Synthesis of Results	
 
Introduction 
 Here we summarize the main results of the study. First we will look at measures 
of glucose metabolism namely fasting plasma glucose and hemoglobin A1c. Then we will 
look at other measures of obesity including body weight, body mass index, and waist 
circumference. We will then look at obesity related comorbidities including hypertension 
and hyperlipidemia. Lastly we will summarize data from other obesity related 
comorbidities, which were not included in the meta analysis due to the heterogeneous 
nature of the data. These will include obstructive sleep apnea, osteoarthritis, infertility, 
gastroesophageal reflux, urinary stress incontinence and venous stasis. Where possible 
we looked at results from each individual procedure type and also compared results  
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PubMed,	Cochrane,	Embase,	CINAHL	1966	citations	screened	initially	
546	non-duplicate	citations	screened	
Inclusion/exclusion	Criteria	applied	 454	articles	excluded	
92	articles	for	full	text	review	
Inclusion/exclusion	Criteria	applied	 78	articles	excluded	 1	article	excluded	during	data	extraction	
13	articles	included	in	the	final	analysis	
Figure 4.1 – PRISMA Diagram 
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between individual procedures to determine if treatment effects were true for each 
surgery type and to help answer the question: is one surgery superior for the treatment of 
obesity and comorbidities in patients with BMI < 35? For cohort studies the experimental 
group was assigned as the surgical group and the control group was assigned as the pre 
surgical group. For RCTs comparing REYGB to LSG gastric bypass was assigned as the 
experimental group and LSG was assigned as the control group. For RCTs comparing 
surgery to medical therapy surgery was considered the experimental group. 95% CIs to 
the left of 0 for continuous variables and 1 for categorical variables was considered 
significant in favor of the surgical or experimental group.  
 
Fasting Plasma Glucose  
 Results of Fasting plasma glucose data are summarized in figure 4.2. Total of 10 
studies included well defined results of glucose metabolism that could be used for meta 
analysis. Remaining 3 studies reported data in terms of improvement of hypoglycemic 
medications or other non standardized outcomes. All data was reported in units of 
mmol/l. Surgical groups had a total of 292 patients versus 293 in the control groups. 
According to predefined analysis using weighted mean difference and random effects 
model there was a significant improvement in glycemic control in the Surgical group 
compared to the control group (WMD -3.24, 95% CI -4.45; -2.02).  Heterogeneity as 
defined by I2 statistic was high at 97% (p < 0.01).  
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Figure 4.2 – Fasting plasma glucose overall results 
 
  
The effect seen on FPG in the pooled data held true in the Roux en y gastric 
bypass group. A total of 263 patients were in the surgery group compared to 264 in the 
control group. Weighted mean difference was -2.86 with 95% CI -4.19; -1.52. 
Heterogeneity was high with I2 = 98% (p<0.01).  
 
Figure 4.3 – Fasting plasma glucose roux en y gastric bypass 
 
 
Total of 2 studies compared sleeve gastrectomy to medical therapy with respect to 
FPG. 29 patients were in each of the surgical and medical groups. Statistically significant 
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difference in FPG between the groups was noted (WMD -5.17, 95% CI -6.82; -3.51). 
Heterogeneity was low with I2 = 0% (p = 0.41). Insufficient data were obtained to 
perform subgroup analysis on patients who underwent adjustable gastric banding 
however these were included in the overall analysis.  
 
Figure 4.4 – Fasting plasma glucose sleeve gastrectomy 
 
 
Only two surgical groups were available for direct comparison by RCT. 2 studies 
compared roux en y gastric bypass to sleeve gastrectomy. Roux en y gastric bypass group 
was considered the experimental group and sleeve gastrectomy was taken as the control 
group. Total of 57 patients were in the gastric bypass group versus 58 patients in the 
sleeve gastrectomy group. No statistically significant difference was seen between the 
two surgical groups with respect to change in FPG (WMD -1.14, 95% CI -3.29; 1.02). 
Heterogeneity was high with I2 = 93% (p < 0.01).  
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Figure 4.5 – Fasting plasma glucose REYGB versus LSG 
 
 
Hemoglobin A1c 
 Total of 9 studies included data where hemoglobin A1c was well defined. Others 
gave vague descriptions such as ‘improved’ without meaningful descriptions and were 
excluded here. Weighted mean difference and 95% confidence intervals were obtained 
for the overall group looking at all surgical interventions versus control groups. The 
overall results show that there is a statistically significant improvement in hemoglobin 
A1c in the surgical groups versus control (WMD -2.34, 95% CI -3.45; -1.22). 
Heterogeneity as calculated using I2 statistic was high at 96% (p < 0.01).  
 
 
Figure 4.6 – HbA1c overall results 
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7 of the 9 included studies involved gastric bypass. Total of 226 patients were 
included in the experimental group versus 227 in the control group. A statistically 
significant improvement was seen in the REYGB group compared to control group 
(WMD -2.25, 95% CI -3.55; -0.96). Heterogeneity was high with I2 = 97% (p<0.01).  
 
Figure 4.7 – HbA1c Roux en Y gastric bypass 
 
 
 2 studies compared sleeve gastrectomy to medical therapy. Total of 29 patients 
were included in each group. Statistically significant improvement in HbA1c was 
maintained across these studies (WMD -2.74, 95% CI -3.73; -1.75). Data was insufficient 
to perform a meaningful comparison amongst patients who underwent AGB.  
 
Figure 4.8 – HbA1c Sleeve gastrectomy group 
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Comparison of REYGB versus LSG yielded 2 RCTs with a total of 57 patients in 
the gastric bypass group and 58 in the LSG group. No statistical difference was seen with 
respect to HbA1c between the two surgical procedures (WMD -0.83, 95%CI -2.11; 0.44). 
Heterogeneity was high with I2 =93%.  
 
Figure 4.9 – HbA1c REYGB versus LSG 
 
Body Weight 
 Total of 5 Studies included body weight measured in kilograms. Total of 147 
patients were included in the treatment group compared to 142 studies in the control 
group. Results demonstrated a significant decrease in body weight favoring the treatment 
group (WMD -12.09, 95% CI -19.25; -4.93). Heterogeneity was calculated as high with  
I2 = 95% (p < 0.01).  
 
Figure 4.10 – Body Weight Overall Results 
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4 out of 5 studies that included accurate body weight analysis were done on 
patients undergoing laparoscopic roux en y gastric bypass. One study included patients 
who underwent adjustable gastric banding. Analysis of this group revealed that there was 
a statistically significant difference compared to the control group (WMD -11.39, 95% CI 
-22.49; -0.30). Heterogeneity was high with I 2 = 95% (p < 0.01). No further subgroup 
analysis was possible given the paucity of data reported in the included studies.  
 
Figure 4.11 – Body weight REYGB 
 
 
 Two RCTS included data on body weight. Both compared REYGB to LSG. Total 
of 57 patients in the experimental group versus 58 in the control group. No statistically 
significant difference was seen with respect to body weight amongst the study 
participants (WMD -1.92, 95% CI -7.90; 4.05). Heterogeneity was high with I2 = 71% 
however this result was not statistically significant (p = 0.06).  
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Figure 4.12 – Body weight REYGB versus LSG 
  
Body Mass Index 
 A total of 11 studies included data on body mass index. There were a total of 374 
patients in the treatment group versus 369 in the control group. Results demonstrate a 
statistically significant decrease in BMI for surgery compared to the control group 
(WMD -5.63, 95% CI -6.96; -4.30). Heterogeneity was high with I2 calculated at 97% 
 (p < 0.01).  
 
Figure 4.13 – Body mass index overall results
 
  
6 studies included roux en y gastric bypass in the analysis. There were 160 
patients in the treatment group versus 161 in the control group. The results demonstrate a 
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significant decrease in BMI for patients undergoing REYGB (WMD -4.74, 95% CI -7.65; 
-1.83). Heterogeneity was high with I2 = 98% (p < 0.01).  
 
Figure 4.14 – Body mass index REYGB 
 
 
 2 studies in patients undergoing laparoscopic sleeve gastrectomy included data on 
body mass index. There was a total of 29 patients in each of the experimental and control 
groups. A statistically significant decrease in BMI was seen in these patients (WMD -
8.35, 95% CI -12.46; -4.25). Heterogeneity was high with I2 = 86% (p<0.01).  
 
Figure 4.15 – Body mas index LSG 
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3 studies in patients undergoing adjustable gastric banding reported data on body 
mass index and were included here. There were 185 patients in the surgical group versus 
179 patients in the medical therapy group. Overall a statistically significant difference 
between the two groups was seen (WMD -5.86, 95% CI -7.02; -4.70). Heterogeneity was 
high as I2 statistic was calculated at 90% (p< 0.01).  
 
Figure 4.16 – Body mass index AGB 
 
Lee et. al 2011 and Yang et. al compared Laparoscopic Roux en y gastric bypass 
to sleeve gastrectomy and data on BMI are included here. Total of 57 patients in the 
gastric bypass group versus 58 in the sleeve gastrectomy group. Overall there was a 
statistically significant difference in BMI between the two surgical groups favoring 
gastric bypass (WMD -1.07, 95% CI -1.81; -0.33). Heterogeneity was low with I2 = 22% 
however this result was not statistically significant (p = 0.26).  
 
Figure 4.17 – Body mass index RYGB versus LSG 
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Waist Circumference 
 A total of 4 studies included data on waist circumference. 97 patients were in the 
experimental group with 98 patients in the control group. Overall the results were in favor 
of the experimental group with a significant decrease in waist circumference (WMD   
- 10.29, 95% CI -19.96; -0.63). Heterogeneity was high with I2 = 98% (p < 0.01).  
 
Figure 4.18 – Waist circumference overall results 
 
  
3 out of 4 studies that included data on waist circumference were done on patients 
undergoing roux en y gastric bypass and these are included here. 77 patients were 
included in the treatment group while 78 were included in the control group. Interestingly 
the results show that there was no significant difference in the experimental group versus 
the control group (WMD -9.19, 95% CI -20.67; 2.29). Heterogeneity was high with I2 = 
98% (p < 0.01).  
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Figure 4.19 – Waist circumference RYGB 
 
  
2 RCTS compared RYGB to LSG and data on waist circumference are presented 
here. Total of 57 patients in the RYGB group versus 58 in the LSG group. Overall a 
statistically significant decrease in waist circumference was seen in favor of gastric 
bypass (WMD -3.51, -6.99; -0.03). Heterogeneity was high with I2 = 71%, however this 
result was not significant (p = 0.06).  
 
Figure 4.20 – Waist circumference RYGB versus LSG 
 
 
Hypertension 
 We used rate of resolution of hypertension as a measure of success of surgery 
versus control. Blood pressure measurements were given in mmHg unless otherwise 
specified. Resolution was defined as normalized blood pressure and off antihypertensive 
medications. Odds ratios were calculated as per Cochrane – mantel – hantzel method. A 
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total of 6 studies included accurate data on hypertension and rates of resolution. There 
were 261 patients in the experimental group and 262 in the control group. According to 
pre defined statistical analysis there was a significantly higher rate of resolution of 
hypertension in the experimental group (OR 0.20, 95% CI 0.08; 0.51). Heterogeneity was 
high with I2 = 65% (p = 0.01). No randomized controlled trials were available for 
comparison here as insufficient data was reported in these studies with respect to 
hypertension.  
 
Figure 4.21 – Resolution of Hypertension Overall Results 
 
  
4 studies involving patients who underwent roux en y gastric bypass included data 
on resolution of hypertension. There were a total of 115 patients in the experimental 
group and 116 in the control group. Overall there was a statistically significant rate of 
improvement in the surgical group compared to control (OR 0.14, 95% CI 0.03; 0.65). 
Heterogeneity was high with I2 = 75% (p < 0.01).  
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Figure 4.22 – Resolution of Hypertension RYGB 
 
 2 remaining studies involved patients undergoing adjustable gastric banding. 
There were a total of 146 patients in the surgical group and 146 in the group who 
underwent medical therapy. Overall there was a significant difference in the rate of 
resolution of hypertension favoring surgery (OR 0.35, 95% CI 0.17; 0.75). Heterogeneity 
was low in this comparison with I2 = 0%, however this result was not significant (p = 
0.56).  
 
Figure 4.23 – Resolution of Hypertension AGB 
 
 
Dyslipidemia 
 We looked at rates of resolution of dyslipidemia that was defined as normal 
cholesterol and triglyceride panel and discontinuation of any lipid lowering medications. 
Absolute values of triglycerides, total cholesterol, low density lipoprotein (LDL) and high 
	 66	
density lipoprotein (HDL) were sometimes provided but not in all studies. Normal values 
for lipid parameters were also inconsistently reported. A total of 5 studies included 
complete data on resolution of dyslipidemia. All of these studies were done on patients 
who underwent roux en y gastric bypass therefore no other surgical groups were available 
for sub group analysis. A total of 168 patients were in the experimental group and 169 
were in the control group. Overall the results were in favor of surgery with a statistically 
significant difference in the 2 groups (OR 0.10, 95% CI 0.02; 0.48). Heterogeneity was 
high with I2 = 78% (p < 0.01).  
 
Figure 4.24 – Resolution of Dyslipidemia Overall Results 
 
 
Other Obesity related comorbidities 
 Some authors studied other variables related to obesity in this patient population 
however there was insufficient data across studies to perform a meta analysis. Obstructive 
sleep apnea was seen to be resolved in anywhere from 7%-100% of patients. 
Osteoarthritis was improved in 33-47% of patients. Infertility has been shown to be 
associated with obesity and the included studies here reported a range of 7-50% 
improvement in fertility after surgery. Gastroesophageal reflux was improved in 7-75% 
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of patients. Urinary stress incontinence improved in 20% and venous stasis improved in 
7%.  These results indicate that although there was a wide range of results across studies 
and that bariatric surgery in moderately obese patients can be an effective treatment for a 
number of less commonly explored obesity related comorbidities.  
 
4.5 - Risk of Bias Across Studies 
 Significant heterogeneity was seen across included studies with I2 values ranging 
from 78% to 98%. For several of the variables studied there was slight to moderate 
heterogeneity reported with I2 values ranging from 0% to 71% however for these analyses 
the calculated value of I2 was not statistically significant. A funnel plot was constructed to 
assess publication bias and this revealed a fairly symmetrical graph, especially given the 
relatively low number of studies included in the analysis. Several studies did cause the 
graph to skew somewhat to the left that may indicate that studies with smaller numbers of 
patients may have had a slightly exaggerated treatment effect. Based on this visual 
representation we conclude that there is a slight possibility of bias in the presented 
studies.  
 
 
 
 
 
 
 
	 68	
Figure 4.25 – Funnel Plot (FPG Surgery versus control) 
 
 
 
4.6 - Safety profile of surgery 
 In order to make a truly strong recommendation regarding surgery for moderately 
obese individuals, one would have to ensure that the safety profile is comparable to that 
seen in morbidly obese subjects. It would be very difficult to make a recommendation if 
the safety profile was less favorable than seen with morbidly obese patients. Encinosa et. 
al. examined insurance claims for almost 10,000 patients undergoing bariatric surgery in 
the United States between 2001 and 2006 and found that the risk adjusted rates of 
readmissions from complications during bariatric surgery was 6.8%41. With increasing 
procedures being performed laparoscopically the mortality rate has declined to 0.1%17. 
Most studies included in this meta analysis had small numbers of patients however there 
were no mortalities reported in any of the studies included here. Yang et. al. reported no 
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major complications or deaths in their group of patients undergoing LREYGB and LSG. 
There were minor complications in 5.5% of patients including GERD and minor anemia 
not requiring blood transfusion42. Parikh et. al. reported no perioperative complications in 
their patients undergoing AGB. All patients had their surgery performed laparoscopically 
and were discharged home from hospital within 24 hours43. Cohen et. al. 2012 reported 
no major surgical complications or mortality in their cohort of patients undergoing 
LREYGB9. These results were comparable across studies and certainly comparable to 
that seen in morbidly obese subjects undergoing bariatric surgery, in some cases the 
safety profile was more favorable compared to morbidly obese subjects. The way in 
which complications is reported amongst studies is quite heterogeneous making a pooled 
estimate of complications of limited value.  
 
Chapter 5 – Discussion 
 To our knowledge this is the first systematic review and meta analysis to 
exclusively explore patients with BMI < 35. We also limited our analysis to the highest 
levels of evidence available, that being randomized controlled trials and prospective 
cohort studies. We considered commonly measured variables including FPG, HbA1c, 
body weight, BMI, waist circumference and resolution of hypertension and dyslipidemia. 
We also considered less commonly studied variables including obstructive sleep apnea, 
osteoarthritis, infertility, gastroesophageal reflux, urinary stress incontinence and venous 
stasis.  
Our results indicate that for patients with moderate obesity (BMI < 35), surgery 
appears to be superior to medical therapy in terms of weight loss and treatment and 
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resolution of obesity related comorbidities. Specifically, we found that surgery is superior 
in terms of treating diabetes mellitus as fasting plasma glucose and HbA1c were 
significantly lower in the surgical group compared to medical therapy. Other sub group 
analysis confirmed that surgery is superior to medical therapy in terms of weight loss, 
BMI loss, decreased waist circumference, and resolution of hypertension and 
dyslipidemia. This result was mostly consistent across each of the surgical procedures 
that were reviewed, namely roux en y gastric bypass, adjustable gastric banding and 
sleeve gastrectomy. This finding was also consistent between cohort studies and RCTs 
that compared surgery to medical therapy.  
 There is also much debate in the literature regarding which if any bariatric 
procedure is superior and this remains controversial particularly in the setting of morbidly 
obese patients. The question of superiority amongst bariatric surgical procedures is even 
more crucial when considering their application to a patient population where its use is 
even more controversial. We were able to make a direct comparison in this meta analysis 
between roux en y gastric bypass and laparoscopic sleeve gastrectomy as there were 2 
randomized controlled trials that met our inclusion criteria and both randomized patients 
to either RYGB or LSG. We found that there was no significant statistical difference in 
the effect on FPG or HbA1c between either procedure meaning that both of these surgical 
procedures will be equally effective in the treatment of diabetes mellitus in patients with 
BMI < 35. The confidence intervals in this part of the analysis were very wide which 
certainly is a limitation in interpreting these results. We did however find that there was a 
significant decrease in waist circumference and BMI with RYGB compared to LSG. 
There was insufficient data to determine if either procedure would be superior at treating 
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hypertension, dyslipidemia or other obesity related comorbidities. An interesting finding 
was the fact that despite improved BMI and waist circumference with RYGB, there did 
not seem to be any difference in body weight between the two surgical procedures. Yang 
et. al. demonstrated a significant difference in the starting body weight between the two 
surgical groups. Patients who underwent RYGB had a starting body weight of 94.3kg 
compared to 88.4kg in the sleeve gastrectomy group. Therefore it stands to reason that 
the LSG group could plausibly have a lower weight after surgery compared to the RYGB 
group. This systematic flaw could have been circumvented by calculating change in body 
weight and making that comparison however the data was too heterogeneous to allow this 
data to be collected and analyzed accurately for each of the included studies. For 
example, in some studies only the post surgical body weight was given making the 
change in body weight impossible to calculate. We attempted to get this information from 
study authors however we were unable to obtain any further data.  
 It is also a curious result that BMI in the RYGB group was significantly lower 
given that there was no significant difference in body weight. Given that the pre surgical 
BMI was not significantly different (32.3 +/- 2.4 RYGB versus 31.8 +/- 3.0 LSG) one can 
deduce that the heights of the study participants was substantially different amongst both 
groups, however this data was not included in any of the studies. In other words absolute 
weight loss was higher in the RYGB group however the starting weights were different 
so that the absolute difference in BMI was greater in the RYGB without any significant 
difference in the post surgical weights between the two groups.  
 A similar discrepancy was seen with respect to waist circumference. Comparison 
of all studies revealed a significant reduction in waist circumference favoring the surgical 
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group. There was also a significant difference when RYGB was compared to LSG 
favoring the bypass group. However when RYGB was compared on its own during 
subgroup analysis no significant difference was seen. The data seen in Scopinaro et. al., 
which was included in this subgroup analysis, appears to be an outlier and also appears to 
skew the data into non significance. On this basis one can conclude that RYGB is more 
effective than either LSG or medical therapy in reducing waist circumference. The end 
result is that based on our analysis RYGB appears to have better results with respect to 
BMI, waist circumference and possibly weight loss when compared to LSG. There was 
no difference in parameters of glucose metabolism (FPG and HbA1c).  
 Despite using the highest level of evidence available this study did have several 
limitations. There was significant heterogeneity across studies included in this analysis. 
Although several studies did have I2 values of zero, which would indicate essentially no 
heterogeneity, these findings were not statistically significant. Majority of studies had I2 
values >90% which would indicate a high level of heterogeneity. More accurate analysis 
would potentially be performed using studies with less heterogeneity, however we were 
limited in this regard by the relatively small number of studies included in the analysis. 
There are a number of factors which could explain high levels of heterogeneity between 
studies including: sample size, inclusion criteria of individual studies and confounding 
variables such as variations in surgical technique. Excluding studies with high levels of 
heterogeneity would have left us with insufficient number of studies to perform 
meaningful analysis. Data extraction was also somewhat heterogeneous across the studies 
which potentially led to this phenomenon. We also grouped randomized and non 
randomized data during the analysis. This approach does have some inherent statistical 
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limitations which no doubt contributed in part to the anomalies that were seen in some of 
the results with respect to body weight and waist circumference. We felt this approach 
would be most appropriate for this study given that we were comparing several different 
obesity related comorbidities and surgical procedures and also given that we have 
relatively few studies for comparison. We considered performing subgroup analysis of 
only randomized controlled trials however we felt that comparing 2 studies comparing 
surgical procedures and 2 studies looking at surgery versus medical therapy would lead to 
significant heterogeneity given that comparison of 2 RCTs comparing surgical groups 
already had a significant level of heterogeneity. We felt that this further subgroup 
analysis would not lend any meaningful results to our analysis. There was also 
heterogeneity with respect to risk of bias. 7 of the included studies were assessed 
moderate risk of bias, 3 studies were found to have some concerns, 2 studies had serious 
concerns and one study had low risk of bias. This was also heterogeneous amongst cohort 
studies and RCTs. 6 of the 7 studies assessed moderate level of bias were cohort studies 
assessing RYGB. Both studies assessed serious level of bias were cohort studies looking 
at AGB. As we had analyzed the data looking at each surgery type we felt this subgroup 
analysis would not be meaningful. Similarly because all 3 RCTs that were found to have 
some concerns with respect to bias were analyzing different surgery types we felt this 
subgroup analysis would not be helpful and these were omitted.  
Our study was limited to three different surgical procedures. We felt this was 
prudent given that these procedures are most commonly being performed throughout the 
world and have very good safety profiles and proven efficacy in obese patients. However, 
this does decrease the generalizability of the results and also potentially exclude other 
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surgical procedures that may have favorable results in this patient population. The 
heterogeneity of data reporting amongst studies was a serious limitation. The strength of 
performing a meta analysis comes from the ability to pool data and increase numbers of 
patients for analysis. In many instances data was just too heterogeneous for any 
meaningful analysis. Many studies would have for example ‘improved’ as their endpoint 
of interest instead of variables that are more easily measured. This ultimately limited our 
ability to analyze other obesity related comorbidities such as sleep apnea, infertility, 
urinary incontinence, etc.  
Our review also had a paucity of randomized data. Only 4 of 13 studies included 
data that was collected in a randomized fashion. Future studies looking at the role of 
surgery for moderately obese patients should include well designed randomized 
controlled trials ideally with large numbers of patients. These studies should also have a 
standardized method of reporting outcomes to improve generalizability and interpretation 
of the data. This would also potentially make the studies less heterogeneous and allow 
researchers to explore whether other less commonly reported obesity related 
comorbidities such as sleep apnea can be effectively treated by surgery in this patient 
population. Inclusion of other surgical procedures such as duodenal switch or mini gastric 
bypass will also be essential to see if any significant difference exists with respect to 
moderately obese patients. Other meaningful analysis would be to consider if there is a 
low point in BMI where patients may or may not benefit from surgery. For example 
patients with low BMI (<25) and diabetes have been shown in previous studies to have 
less benefit from surgery as these patients typically have more pancreatic beta cell 
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dysfunction and less peripheral insulin resistance35. Analyzing patients based on class of 
obesity or subgroup of BMI will be useful in this regard.  
 
5.1 – Conclusion 
 Bariatric surgery appears to be effective for the treatment of obesity related 
comorbidities in patients with BMI < 35. Safety profile is comparble to that seen in 
morbidly obese subjects with a relatively low risk of morbidity and mortality. Surgery 
compared to medical therapy offers improved results with respect to fasting plasma 
glucose, Hemoglobin A1c, weight loss, BMI loss, waist circumference, and resolution of 
hypertension and dyslipidemia. Variable rates of improvement are also seen with respect 
to obstructive sleep apnea, osteoarthritis, infertility, gastroesophageal reflux, urinary 
stress incontinence and venous stasis. Roux en y gastric bypass, sleeve gastrectomy and 
adjustable gastric banding when performed laparoscopically are safe and effective 
treatments for moderately obese individuals. While there was no difference between 
RYGB and LSG with respect to FPG and HbA1c, RYGB was associated with improved 
BMI loss and decreased waist circumference.  These surgical procedures should be 
offered to patients with moderate obesity, especially those with related comorbidities and 
should be part of current treatment guidelines for obese individuals. With further studies 
these guidelines can be refined to ensure that the most appropriate surgical procedure can 
be offered to an individual patient.  Future studies should include randomized controlled 
trials with large numbers of patients. These studies should aim to standardize reporting of 
variables such as FPG and HbA1c and where possible should standardize surgical 
procedures.  
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				 							Abbatini	et.	al.	2012	
Risk	of	bias	 Some	concerns	Details	regarding	blinding	and	randomization	were	lacking		
Study	design	 Randomized	controlled	trial	
	
Population	 n	=	18	single	center	Italy	Included	patients	with	BMI	<	35	and	T2DM		
Intervention	 Laparoscopic	sleeve	gastrectomy		
Control	 Conventional	medical	therapy		
Outcome	 T2DM	resolution,	dyslipidemia,	obstructive	sleep	apnea	Hypertension		
Results	 T2DM	and	hypertension	resolution	occurred	In	88.9%	of	patients	Dyslipidemia	was	corrected	in	all	surgical	patients.	Sleep	apnea	was	resolved	in	1	patient.		In	medical	group	all	patients	continued	to	have	T2DM	and		Required	antihypertensive	and	hypolipemic	therapies			
 
 
 
 
 
 
 
 
Table	1	–	Summary	data	Abbatini	et.	al.	201244	
Tables 
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Cohen	et.	al.	2006	
Risk	of	bias	 Moderate	Non	randomized,	non	blinded		
Study	design	 Prospective	Cohort	
Population	 n	=	37	single	center	Brazil	Included	patients	with	BMI	<	35	and	T2DM		
Intervention	 Laparoscopic	roux	en	y	gastric	bypass		
Control	 Pre	surgical	group		
Outcome	 T2DM,	hypertension,	lipid	disorder,	GERD	and	sleep	apnea.	Also	excess	weight	loss		
Results	 At	2	years	of	follow	up	36/37	patients	had	complete	resolution	of	all	obesity	related	comorbidities	studied.	Mean	excess	weight	loss	was	81%			
 
 
 
 
 
 
 
 
 
 
 
 
Table	2	–	Summary	data	Cohen	et.	al.	200645
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Cohen	et.	al.	2012	
Risk	of	bias	 Moderate	Non	randomized,	non	blinded		
Study	design	 Prospective	Cohort	
	
Population	 n	=	66	single	center	Brazil	Included	patients	with	BMI	<	35	and	T2DM		
Intervention	 Laparoscopic	roux	en	y	gastric	bypass		
Control	 Pre	surgical	group		
Outcome	 T2DM	resolution	or	improvement,	waist	circumference,	total	body	weight	loss,	hypertension,	hypercholesterolemia.			
Results	 After	6	years	of	follow	up	T2DM	resolution	was	maintained	in	88%	and	glycemic	improvement	in	11%.	HbA1c	was	also	significantly	reduced.	Weight	loss	did	not	correlate	with	glucose	homeostasis.	Hypertension	and	dyslipidemia	were	also	improved.	Neither	mortality	nor	major	surgical	morbidity	were	observed.																								
Table	3	–	Summary	data	Cohen	et.	al.	20129	
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	DePaula	et.	al.	2008		 	
Study	design	 Prospective	cohort	
Population	 n	=	39	BMI	between	23.4-34.9	kg/m2	Diabetics	with	HbA1c	>	7.5	Multi	center	Brazil	
Intervention	 ileal	interposition	with	sleeve	gastrectomy	(ILSG)	or	ileal	interposition	with	diverted	sleeve	gastrectomy	(ILDSG).			
Control	 Preoperative	group	
Outcome	 BMI,	excess	weight	loss,	resolution	of	diabetes,	perioperative	complications.		
Results	 Average	follow	up	was	7	months.	Major	complications	noted	in	10.3%	and	minor	complications	in	15.4%	of	patients.	Mean	BMI	decreased	from	30.1kg.m2	to	24.9kg/m2.	Diabetes	was	resolved	in	86.9%	of	patients.	Remaining	patients	were	on	single	hypoglycemic	agent	and	no	patients	were	on	insulin	postoperatively.				
 
 
 
 
 
 
 
 
 
 
 
 
Table	4	–	Summary	data	DePaula	et.	al.	200826	
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Dixon	et.	al.	2002		 	
Study	design	 Retrospective	cohort	
Population	 n	=	50	BMI	>	35	with	diabetes	Single	center	Australia	
Intervention	 Laparoscopic	adjustable	gastric	banding	
Control	 Cohort	of	patients	receiving	medical	therapy	
Outcome	 Weight	loss,	resolution	of	comorbidities	and	complications.		
Results	 Total	follow	up	of	one	year.	Mean	excess	weight	loss	was	38%	which	was	statistically	significantly	lower	compared	to	the	control	group.	Significant	improvements	were	also	seen	in	the	surgical	group	with	respect	to	FPG,	HbA1c,	lipid	improvement	and	improvement	in	liver	enzymes.			
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table	5	–	Summary	data	Dixon	et.	al.	200222	
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Huang	et.	al.	2011	
Risk	of	bias	 Moderate	Non	randomized,	non	blinded		
Study	design	 Prospective	Cohort	
	
Population	 n	=	22	single	center	Taiwan	Included	patients	with	BMI	<	35	and	T2DM		
Intervention	 Laparoscopic	roux	en	y	gastric	bypass		
Control	 Pre	surgical	group		
Outcome	 T2DM	resolution	or	improvement,	BMI,	cholesterol	and	triglycerides		
Results	 After	12	months	of	follow	up	14	patients	(63.6%)	showed	T2DM	remission,	6	(27.3%)	showed	glycemic	control	and	2	(9.1%)	showed	improvement.	Comparing	patients	who	had	T2DM	remission	versus	control	or	improvement	there	was	a	significant	difference	in	BMI	and	duration	of	DM	with	patients	who	were	in	remission	having	slightly	higher	BMI	and	shorter	duration	of	DM.	no	difference	was	seen	with	respect	to	cholesterol	and	triglycerides.				
 
 
 
 
 
 
 
 
	Table	6	–	Summary	data	Huang	et.	al.	201146	
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Lanzarini	et.	al.	2013	
Risk	of	bias	 Moderate	Non	randomized,	non	blinded		
Study	design	 Prospective	Cohort	
	
Population	 n	=	31	single	center	Chile	Included	patients	with	BMI	<	35	and	T2DM	Age	between	18	and	65	Adequate	nutritional,	psychological	and	endocrinological	assessments		
Intervention	 Laparoscopic	roux	en	y	gastric	bypass		
Control	 Pre	surgical	group		
Outcome	 T2DM,	use	of	oral	hypoglycemic	agents,	BMI		
Results	 At	36	months	follow	up	BMI	significantly	decreased	to	mean	of	24.7kg/m2.	All	patients	showed	improvement	in	glycemic	control	and	93.6%	met	criteria	for	remission.	Only	one	patient	had	a	postoperative	complication	(hemoperitoneum).				
 
 
 
 
 
 
 
Table	7	–	Summary	data	Lanazarini	et.	al.	201347	
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Lee	et.	al.	2010	
Risk	of	bias	 Moderate	Non	randomized,	non	blinded		
Study	design	 Prospective	Cohort	
	
Population	 n	=	20	single	center	Taiwan	Included	patients	with	BMI	between	25	and	35.		Patients	with	T2DM		
Intervention	 Laparoscopic	sleeve	gastrectomy		
Control	 Pre	surgical	group		
Outcome	 T2DM,	use	of	oral	hypoglycemic	agents,	BMI,	waist	circumference,	excess	weight	loss.			
Results	 At	one	year	follow	up	there	were	significant	improvements	in	BMI,	waist	circumference,	EWL,	fasting	glucose,	and	HbA1c			
 
 
 
 
 
 
 
 
 
Table	8	–	Summary	data	Lee	et.	al.	201048	
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Lee.	et.	al.	2011	
Risk	of	bias	 Low		
Study	design	 Randomized	controlled	trial	
Population	 n	=	60	single	center	Taiwan	Included	patients	with	BMI	between	25	and	35	Age	<	60	Poorly	controlled	T2DM		
Intervention	 Laparoscopic	roux	en	y	gastric	bypass	versus	
Laparoscopic	sleeve	gastrectomy	
	
Control	 Sleeve	gastrectomy	group		
Outcome	 Remission	of	T2DM,	BMI,	waist	circumference,	hypertension,	blood	lipid	levels.			
Results	 At	12	months	after	surgery	there	were	significant	differences	favoring	the	gastric	bypass	group	including	successful	treatment	of	T2DM	which	occurred	in	17	patients	(57%)	as	compared	to	0	in	the	sleeve	gastrectomy	group.	There	were	also	significant	differences	noted	with	respect	to	HDL	and	persistence	of	metabolic	syndrome.	HbA1c	and	FPG	were	significantly	different.	No	major	surgical	complications	in	either	group.				
 
 
 
 
 
 
Table	9	–	Summary	data	Lee	et.	al.	201127	
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Mason	et.	al.	1967		 	
Study	design	 Retrospective	
Population	 Not	well	defined,	perceived	morbidly	obese	patients	
Intervention	 Open	gastric	bypass	
Control	 Cohort	study,	control	group	is	based	on	preoperative	assessment	
Outcome	 Weight	loss,	perioperative	complications,	resolution	of	peptic	ulcer	related	symptoms.		
Results	 Patients	were	operated	over	a	3	year	period.	Average	weight	loss	was	86	pounds.		2	deaths	reported	and	2	major	complications	in	the	follow	up	period.	One	patient	underwent	revisional	surgery	because	of	jejunal	ulcer	however	details	regarding	this	were	lacking	in	the	report.			
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table	10	–	Summary	data	Mason	et.	al.	196710	
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Nocca	et.	al.	2007		 	
Study	design	 Prospective	cohort	
Population	 n	=	167	multicenter	BMI	>	40	or	>	35	with	comorbidities	France,	USA	
Intervention	 Laparoscopic	sleeve	gastrectomy	
Control	 Pre	surgical	group	
Outcome	 Excess	weight	loss,	perioperative	complications.		
Results	 Total	follow	up	duration	of	2	years.	Mean	excess	weight	loss	was	61.5%.	Complication	rate	was	7.4%	with	reoperative	rate	of	4.9%.	Mean	BMI	went	from	45.9kg/m2	to	31.6kg/m2.		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table	11	–	Summary	data	Nocca	et.	al.	200716	
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Noya	et.	al.	1998		 	
Study	design	 Retrospective	
Population	 n	=	10	BMI	<	35	Diabetes,	hypercholesterolemia	and	hypertension	Single	center	Italy	
Intervention	 Biliopancreatic	diversion	
Control	 Preoperative	group	
Outcome	 Glycemic	indices,	resolution	of	hypertension	and	hypercholesterolemia	
Results	 Maximum	follow	up	was	12	months.	All	patients	had	resolution	of	hypertriglyceridemia	and	hypertension.	Mean	BMI	decreased	from	33.2kg/m2	to	30.5kg/m2.	9	of	10	patients	had	normoglycemic	values	postoperatively.			
 
 
 
 
 
 
 
 
 
 
 
 
 
Table	12	–	Summary	data	Noya	et.	al.	199824	
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O’Brien	et.	al.	2006	
Risk	of	bias	 Some	Concerns	Non	blinded		
Study	design	 Randomized	controlled	trial	
	
Population	 n	=	72	single	center	Australia	Included	patients	with	BMI	between	30	and	35		
Intervention	 Laparoscopic	Adjustable	gastric	banding	versus	intense	
medical	therapy	
	
Control	 Medical	group		
Outcome	 Weight	change,	presence	of	metabolic	syndrome	and	quality	of	life			
Results	 Patients	were	followed	for	2	years.		Surgical	group	was	found	to	have	greater	weight	loss	and	excess	weight	loss.	Better	resolution	of	metabolic	syndrome	was	seen	in	the	surgical	group	with	14/15	patients	being	resolved	versus	8/15	in	the	medical	group.	Quality	of	life	was	improved	significantly	more	in	the	surgical	group	than	in	the	medical	group	(100%	versus	38%).	18%	of	surgical	patients	had	complications	related	to	surgery	with	10%	requiring	revisional	surgery.			
 
 
 
 
 
 
 
 
Table	13	–	Summary	data	O’Brien	et.	al.	200649	
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Parikh	et.	al.	2006	
Risk	of	bias	 Serious	Data	given	on	BMI	and	EWL	however	no	statistical	analysis	was	performed	to	compare	treatment	and	control	groups.		
Study	design	 Prospective	Cohort	
	
Population	 n	=	93	Single	center	Australia	Patients	with	BMI	30-35		
Intervention	 Laparoscopic	Adjustable	gastric	band	
	
Control	 Pre	surgical	group	
	
Outcome	 Weight	(kg),	BMI,	Resolution	of	comorbidities	
	
Results	 Weight	reduced	to	72kg	at	3	years	EWL	was	53.8%		BMI	was	reduced	to	18-24	in	34%	of	patients	All	diabetic	patients	were	off	medications	after	surgery	6	of	8	patients	with	hypertension	were	off	medication	4	of	5	patients	with	asthma	were	off	medication	6	of	7	patients	with	sleep	apnea	did	not	need	CPAP	8	of	9	patients	with	arthritis	improved	4	of	11	patients	with	depression	did	not	need	medication			
 
 
 
 
 
 
Table	14	–	Summary	data	Parikh	et.	al.	200643	
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Pories	et.	al.	1982		 	
Study	design	 Randomized	controlled	trial	
Population	 n	=	87	Patients	identified	double	normal	weight	Average	weight	308.5	pounds		Range	219-491	pounds	Single	center	USA	
Intervention	 Randomized	to	open	gastric	bypass	versus	gastric	partition	
Control	 Gastric	partition	group	
Outcome	 Weight	loss,	complications.		
Results	 Total	follow	up	was	15	months.	Gastric	bypass	had	superior	weight	loss	and	at	that	point	randomization	was	discontinued	and	patients	exclusively	underwent	gastric	bypass.	At	18	months	follow	up	gastric	bypass	had	surpassed	gastric	partition	in	terms	of	weight	loss	by	68	pounds	which	was	statistically	significant.	Complications	were	comparable	between	groups.		
 
 
 
 
 
 
 
 
 
 
 
 
 
Table	15	–	Summary	data	Pories	et.	al.	198221	
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Scopinaro	et.	al.	2014	
Risk	of	bias	 Moderate	Non	randomized,	non	blinded		
Study	design	 Prospective	Cohort/	Matched	Case	Control	
	
Population	 n	=	20	(27	matched	controls	who	underwent	medical	therapy)	single	center	Italy	Included	patients	with	BMI	between	30	and	34.9.	Age	35-70	years		Patients	with	T2DM	Patients	compared	to	post	surgical	versus	baseline	and	also	to	matched	controls.			
Intervention	 Laparoscopic	roux-en-Y	gastric	bypass		
Control	 Pre	surgical	group		
Outcome	 T2DM,	body	weight,	BMI,	waist	circumference,	hypertension,	triglycerides	and	cholesterol	values.		
Results	 Significant	improvements	in	body	weight,	BMI,	waist	circumference,	fasting	plasma	glucose,	HbA1c	as	well	as	resolution	of	hypertension,	hypercholesterolemia	and	hypertriglyceridemia.	Body	weight	and	BMI	were	significantly	improved	compared	to	control	patients	however	effects	on	comorbidities	were	not	translated	to	this	group.	No	mortalities,	1	case	of	perioperative	bleeding	was	noted.				
 
 
 
 
Table	16	–	Summary	data	Scopinaro	et.	al.	201450	
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Serrot	et.	al.	2011		 	
Study	design	 Retrospective	matched	case	control	
Population	 n	=	34	BMI	<	35	Diabetes	Single	center	USA	
Intervention	 Laparoscopic	roux	en	y	gastric	bypass	
Control	 Medical	therapy	
Outcome	 BMI,	HbA1c,	medication	use,	hypertension	and	LDL	cholesterol.		
Results	 Maximum	follow	up	was	34	months.	Surgical	group	had	change	in	BMI	from	34.6+/-0.8	kg/m2	to	25.8+/-2.5	kg/m2	compared	to	essentially	no	change	in	the	medical	group	from	34.1+/-1.0	kg/m2	to	34.3+/-2.1	kg/m2	(	p	<	0.001).	HbA1c	decreased	in	the	REYGB	group	from	8.2	+/-2.0	to	6.1+/-2.7	but	did	not	change	in	the	medical	group	(7.0+/-0.7	to	7.1+/-1.8	P	<	0.001).	Blood	pressure	and	LDL	cholesterol	did	not	significantly	change	in	either	group.	Fewer	patients	in	the	surgical	group	were	taking	medications	for	glycemic	control	at	the	end	of	the	study	with	71%	of	patients	taking	less	medications	at	one	year	compared	to	6%	in	the	non	surgical	group	(p	<	0.001).		
 
 
 
 
 
 
 
 
 
Table	17	–	Summary	data	Serrot	et.	al.	20114	
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Sultan	et.	al.	2009	
Risk	of	bias	 Serious	Statistical	analysis	was	substandard		Only	descriptives	given	with	no	analysis	to		Determine	level	of	significance		
Study	design	 Prospective	Cohort	
	
Population	 n	=	53	single	center	USA	Included	patients	with	BMI	<	35		
Intervention	 Laparoscopic	adjustable	gastric	banding		
Control	 Pre	surgical	group		
Outcome	 	BMI,	weight	loss,	excess	weight	loss	and		Resolution	of	comorbidities.		Surgical	complications		
Results	 BMI	decreased	to	25.8	at	2	years	of	follow	up.		EWL	69.7%	13.2%	rate	of	complications.	
		
 
 
 
 
 
 
 
 
Table	18	–	Summary	data	Sultan	et.	al.	200951	
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Wittgrove	et.	al.	1996		 	
Study	design	 Prospective	Cohort	
Population	 n	=	27	BMI	>	40	or	BMI	>	35	with	comorbidities	Single	center	USA	
Intervention	 Laparoscopic	roux	en	y	gastric	bypass	
Control	 Pre	operative	group	
Outcome	 Weight	loss,	resolution	of	comorbidities,	perioperative	complications.	
Results	 Follow	up	for	total	of	18	months.	Mean	excess	weight	loss	of	80%.	Obesity	related	comorbidities	resolved	in	98%.	9	patients	suffered	complications	with	one	anastomotic	leak.	Remainder	of	patients	were	managed	conservatively.			
 
 
 
 
 
 
 
 
 
 
 
 
Table	19	–	Summary	data	Wittgrove	et.	al.	199615	
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Yang	et.	al.	2015	
Risk	of	bias	 Some	Concerns	Details	regarding	blinding	were	lacking		
Study	design	 Randomized	controlled	trial	
	
Population	 n	=	55	single	center	China	Included	patients	with	BMI	between	28	and	35	HbA1c	>/=	7.0%		
Intervention	 Laparoscopic	roux	en	y	gastric	bypass	versus	
laparoscopic	sleeve	gastrectomy	
	
Control	 Sleeve	gastrectomy	group		
Outcome	 Percentage	excess	weight	loss,	BMI,	waist	circumference,	HbA1c,	FPG	and	serum	lipid	levels.				
Results	 After	3	years	of	follow	up	there	were	no	significant	differences	between	surgical	groups	with	respect	to	HbA1c,	serum	lipids	and	FPG.	Gastric	bypass	resulted	in	significantly	greater	excess	weight	loss	and	change	in	BMI	than	sleeve	gastrectomy.			
 
 
 
 
 
 
Table	20	–	Summary	data	Yang	et.	al.	201542	
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Zhu	et.	al.	2012	
Risk	of	bias	 Moderate	Non	randomized,	non	blinded		
Study	design	 Prospective	Cohort	
	
Population	 n	=	30	single	center	China	Included	patients	with	BMI	<	35			
Intervention	 Laparoscopic	roux	en	y	gastric	bypass	
	
Control	 Pre	surgical	group		
Outcome	 T2DM,	BMI,	waist	circumference		
Results	 Significant	reduction	in	HbA1c	was	noted	at	one	year	of	follow	up.	T2DM	was	completely	resolved	in	9	cases.	Significant	improvements	were	also	noted	in	BMI,	waist	circumference,	fasting	plasma	glucose	and	BMI.	No	significant	perioperative	complications	were	reported.																			
Table	21	–	Summary	data	Zhu	et.	al.	201228	
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				Table	22	–	Summary	of	study	characteristics				 Risk	of	Bias	 Study	Design	 No.	of	patients	 Country	 Inclusion	criteria	 Intervention	 Control	 Outcome	 Results	Abbatini	et.	al.	2012	 Some	concerns		 Randomized	controlled	trial	 18	 Italy	(single	center)	 BMI	<35	with	T2DM	 LSG	 Medical	therapy	 T2DM	resolution,	dyslipidemia,OSA	and	HTN	 88.9%	of	patients	had	resolved	T2DM	and	hypertension	.	Dyslipidemia	resolved	in	all	surgical	patients	Cohen	et.	al.	2006	 Moderate		 Prospective	cohort	 37	 Brazil	(single	center)	 BMI	<35	with	T2DM	 LREYGB	 Pre-surgical	group	 T2DM,	HTN,	lipid	disorder,	GERD,	OSA	and	excess	weight	loss	 36/37	patients	had	complete	resolution	of	comorbidities		81%	EWL	Cohen	et.	al.	2012	 Moderate		 Prospective	cohort	 66	 Brazil	(single	center)	 BMI	<35	with	T2DM	 LREYGB	 Pre-surgical	group	 T2DM,	waist	circumference,	total	weight	loss,	HTN,	hypercholesterolemia	 88%	resolution	T2DM	at	6	years,	glycemic	improvement	in	11%,		Huang	et.	al.	2011	 Moderate		 Prospective	cohort	 22	 Taiwan	(single	center)	 BMI	<35	with	T2DM	 LREYGB	 Pre-surgical	group	 T2DM	resolution	or	improvement,	BMI,	cholesterol,	triglycerides	 Follow	up	14	patients,	at	12	months.	63.6%	T2DM	remission,	27.3%	glycemic	control	Lanzarini	et.	al.	2013		 Moderate		 Prospective	cohort	 31	 Chile	(single	center)	 BMI	<35	with	T2DM	and	age	18-65	 LREYGB	 Pre-surgical	group	 T2DM,	use	of	oral	hypoglycemic	agents,	BMI		 BMI	decreased	by	mean	24.7kg/m2,	all	had	improved	glycemic	control	and	93.6%	in	remission.		Lee	et.	al.	2010	 Moderate		 Prospective	cohort	 20	 Taiwan	(single	center)	 BMI	25-35	with	T2DM	 LSG	 Pre-surgical	group	 T2DM,	use	of	oral	hypoglycemic	agents,	BMI,	waist	circumference,	excess	weight	loss.			
Significant	improvements	in	BMI,	waist	circumference,	excess	weight	loss,	fasting	glucose	and	HbA1C	at	one	year	Lee.	et.	al.	2011	 Low	 Randomized	controlled	trial	 60	 Taiwan	(single	center)	 BMI	25-35,	age	30	-	60,	poorly	controlled	T2DM	
LREYGB	 LSG	 Remission	of	T2DM,	BMI,	waist	circumference,	hypertension,	blood	lipid	levels.		
93%	remission		T2DM	in	LREYGB	compared	to	47%	in	LSG	at	12	months	follow	up.	Significant	differences	in	HbA1C,	FPG	and	hyperlipidemia	favoring	LREYGB	O’Brien	et.	al.	2006	 Some	concerns		 Randomized	controlled	trial	 72	 Australia	(single	center)	 BMI	30-35	 Laparoscopic	adjustable	gastric	band	 Medical	therapy	 Weight	change,	presence	of	metabolic	syndrome,	change	in	quality	of	life	
Greater	weight	loss	in	surgical	group.	Resolution	of	metabolic	syndrome	in	14/15	patients	in	surgical	group		Parikh	et.	al.	2006	 Serious		 Prospective	cohort	 93	 Australia	(single	center)	 BMI	30-35	 Laparoscopic	adjustable	gastric	band	 Pre-surgical	group	 Weight,	BMI,	resolution	of	comorbidities	(asthma,	diabetes,	hypertension,	sleep	apnea)	
Mean	weight	reduced	from	98	to	72	kg	at	2	years,	BMI	reduced	to	18-24	in	34%,	all	diabetic	patients	off	medications	at	2	years.		Scopinaro	et.	al.	2014	 Moderate		 Prospective	cohort/matched	case	control	 20	 Italy	(single	center)	 BMI	30-35,	aged	35-70	with	T2DM	 LREYGB	 Pre-surgical	and	matched	controls	
T2DM,	body	weight,	BMI,	waist	circumference,	hypertension,	triglycerides,	cholesterol	
Improvements	in	body	weight,	BMI,	waist	circumference,	FPG,	HbA1C,	resolution	of	HTN,	hypercholesterolemia		Sultan	et.	al.	2009	 Serious		 Prospective	cohort	 53	 USA	(single	center)	 BMI	<35	 Laparoscopic	adjustable	gastric	band	 Pre-surgical	group	 BMI,	weight	loss,	excess	weight	loss,	resolution	of	comorbidities	and	surgical	complications	
BMI	decreased	to	mean	of	25.8	at	2	year	follow	up.	Excess	weight	loss	of	69.7%.	13.2%	rate	of	complications		Yang	et.	al.	2015	 Some		 Randomized	controlled	trial	 55	 China	(single	center)	 BMI	28-35	with	HbA1C	>/=	7.0%	
LREYGB	 LSG	 Excess	weight	loss,	BMI,	waist	circumference,	HbA1C,	FPG,	serum	lipid	levels	
LREYGB	had	significantly	improved	excess	weight	loss	and	decreased	BMI		Zhu	et.	al.	2012	 Moderate		 Prospective	cohort	 30	 China	(single	center)	 BMI	<35	 LREYGB	 Pre-surgical	group	 T2DM,	BMI,	waist	circumference	 Significant	reduction	in	HbA1C	and	improvements	in	BMI,	WC,	and	FPG	in	surgical	group						
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Esophagus	
Stomach	
Duodenum	
Appendix	1	–	Normal	Gastric	anatomy	
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Gastric	pouch	
Gastrojejunostomy	
Small	bowel	anastamosis	
Appendix	2	–	Roux-en-Y	gastric	bypass	diagram	
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Gastric	sleeve	
Resected	portion	
of	stomach	
Esophagus	
Duodenum	
Appendix	3	–	sleeve	gastrectomy	diagram	
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Subcutaneous	
port	
Appendix	4	–	adjustable	gastric	band	diagram	
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Appendix 5 – List of search terms/ search strategy 
 
1     exp Bariatrics/ (11647) 
2     Anastomosis, Roux-en-Y/ (2502) 
3     Biliopancreatic Diversion/ (675) 
4     (bariatric$ or gastric bypass or Gastroplast$ or Lipectom$ or jejunoileal bypass or gastric 
band$ or biliopancreatic diversion$).tw. (11379) 
5     ((vertical or sleeve) adj2 gastrectom$).tw. (652) 
6     (weight loss adj2 (surg$ or operat$)).tw. (959) 
7     (obes$ adj2 (surg$ or operat$)).tw. (1671) 
8     LAGB.tw. (549) 
9     lap band$.tw. (214) 
10     Roux-en-Y.tw. (4719) 
11     duodenal switch$.tw. (350) 
12     or/1-11 (19656) 
13     ((bmi or body mass index) adj3 ("25$" or "26$" or "27$" or "28$" or "29$" or "30$" or "31$" 
or "32$" or "33$" or "34$")).tw. (20377) 
14     bmi < 35$.tw. (644) 
15     bmi<35$.tw. (56) 
16     body mass index < 35$.tw. (199) 
17     bmi less than 35$.tw. (5) 
18     body mass index less than 35$.tw. (10) 
19     bmi lower than 35$.tw. (6) 
20     bmi below 35$.tw. (3) 
21     body mass index below 35$.tw. (1) 
22     (non adj2 obes$).tw. (6525) 
23     (moderat$ adj2 obes$).tw. (863) 
24     (class 1 adj1 obes$).tw. (28) 
25     normal weight.tw. (9030) 
26     or/13-25 (34299) 
27     12 and 26 (1226) 
28     animals/ not humans/ (3611731) 
29     27 not 28 (1210) 
30     "Diabetes Remission and insulin secretion after gastric bypass in patients with body mass 
index".ti. (1) 
31     "Effect of Laparoscopic mini gastric bypass for type 2 diabetes mellitus".ti. (1) 
32     "Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating 
in the ASMBS bariatric surgery center".ti. (1) 
33     "Outcomes of bariatric surgery in patients with body mass index".ti. (1) 
34     "laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients".ti.  
35     or/30-34 (5) 
36     29 or 35 (1210) 
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Appendix 6 – Risk of Bias Assessment (ROBINS-I) tool – Cohen et. al. 2006 		
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Appendix 7 – Risk of Bias Assessment (ROBINS-I) tool – Cohen et. al. 2012 
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Appendix 8 – Risk of Bias Assessment (ROBINS-I) tool – Huang et. al. 2011 
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Appendix 9: Risk of Bias Assessment (ROBINS-I) tool – Lanzarini et. al. 2013 
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Appendix 10 – Risk of Bias Assessment (ROBINS-I) tool – Lee et. al. 2010 
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Appendix 11 – Risk of Bias Assessment (ROBINS-I) tool – Parikh et. al. 2006 
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Appendix 12 – Risk of Bias Assessment (ROBINS-I) tool – Scopinaro et. al. 2014 
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Appendix 13 – Risk of Bias Assessment (ROBINS-I) tool – Sultan et. al. 2008 
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Appendix 14 – Risk of Bias Assessment (ROBINS-I) tool – Zhu et. al. 2012 
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Appendix 15 – Risk of Bias Assessment (ROB 2.0) tool – Abbatini et. al. 2012 
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Appendix 16 – Risk of Bias Assessment (ROB 2.0) tool - Lee et. al. 2011 
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Appendix 17 – Risk of Bias Assessment (ROB 2.0) tool – Obrien et. al. 2006 
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Appendix 18 – Risk of Bias Assessment (ROB 2.0) tool – Yang et. al. 2015 
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